
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">Oncotarget</journal-id><journal-id journal-id-type="iso-abbrev">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">Oncotarget</journal-id><journal-id journal-id-type="publisher-id">ImpactJ</journal-id><journal-title-group><journal-title>Oncotarget</journal-title></journal-title-group><issn pub-type="epub">1949-2553</issn><publisher><publisher-name>Impact Journals LLC</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27259239</article-id><article-id pub-id-type="pmc">5173106</article-id><article-id pub-id-type="publisher-id">9740</article-id><article-id pub-id-type="doi">10.18632/oncotarget.9740</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Paper</subject></subj-group></article-categories><title-group><article-title>Candidate genes and pathways downstream of PAX8 involved in ovarian high-grade serous carcinoma</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes"><name><surname>de Cristofaro</surname><given-names>Tiziana</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author" equal-contrib="yes"><name><surname>Di Palma</surname><given-names>Tina</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Soriano</surname><given-names>Amata Amy</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Monticelli</surname><given-names>Antonella</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib><contrib contrib-type="author"><name><surname>Affinito</surname><given-names>Ornella</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Cocozza</surname><given-names>Sergio</given-names></name><xref ref-type="aff" rid="A2"><sup>2</sup></xref></contrib><contrib contrib-type="author"><name><surname>Zannini</surname><given-names>Mariastella</given-names></name><xref ref-type="aff" rid="A1"><sup>1</sup></xref></contrib></contrib-group><aff id="A1"><sup>1</sup> IEOS, Institute of Experimental Endocrinology and Oncology &#x0201c;G. Salvatore&#x0201d;, National Research Council, Naples, Italy</aff><aff id="A2"><sup>2</sup> Department of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy</aff><author-notes><corresp id="cor1"><bold>Correspondence to:</bold> Mariastella Zannini, <email>s.zannini@ieos.cnr.it</email></corresp></author-notes><pub-date pub-type="collection"><day>5</day><month>7</month><year>2016</year></pub-date><pub-date pub-type="epub"><day>31</day><month>5</month><year>2016</year></pub-date><volume>7</volume><issue>27</issue><fpage>41929</fpage><lpage>41947</lpage><history><date date-type="received"><day>24</day><month>3</month><year>2016</year></date><date date-type="accepted"><day>16</day><month>5</month><year>2016</year></date></history><permissions><copyright-statement>Copyright: &#x000a9; 2016 de Cristofaro et al.</copyright-statement><copyright-year>2016</copyright-year><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.5/"><license-p>This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.</license-p></license></permissions><abstract><p>Understanding the biology and molecular pathogenesis of ovarian epithelial cancer (EOC) is key to developing improved diagnostic and prognostic indicators and effective therapies. Although research has traditionally focused on the hypothesis that high-grade serous carcinoma (HGSC) arises from the ovarian surface epithelium (OSE), recent studies suggest that additional sites of origin exist and a substantial proportion of cases may arise from precursor lesions located in the Fallopian tubal epithelium (FTE). In FTE cells, the transcription factor PAX8 is a marker of the secretory cell lineage and its expression is retained in 96% of EOC. We have recently reported that PAX8 is involved in the tumorigenic phenotype of ovarian cancer cells. In this study, to uncover genes and pathways downstream of PAX8 involved in ovarian carcinoma we have determined the molecular profiles of ovarian cancer cells and in parallel of Fallopian tube epithelial cells by means of a silencing approach followed by an RNA-seq analysis. Interestingly, we highlighted the involvement of pathways like WNT signaling, epithelial-mesenchymal transition, p53 and apoptosis. We believe that our analysis has led to the identification of candidate genes and pathways regulated by PAX8 that could be additional targets for the therapy of ovarian carcinoma.</p></abstract><kwd-group><kwd>PAX8</kwd><kwd>ovarian cancer</kwd><kwd>fallopian tube secretory epithelial cells</kwd><kwd>RNA-seq</kwd><kwd>transcriptional networks</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>INTRODUCTION</title><p>Ovarian cancer, like other cancers, is a spectrum of diseases and not a single disease entity [<xref rid="R1" ref-type="bibr">1</xref>]. Malignant surface epithelial tumors (carcinomas) are the most common ovarian cancers, accounting for 90% of the cases. These tumors are divided in four major histotypes: serous, mucinous, endometrioid and clear cell. Of these, high-grade serous carcinoma (HGSC) is the most common and lethal histotype, associated with abnormalities of <italic>BRCA1, BRCA2</italic> and p53 [<xref rid="R2" ref-type="bibr">2</xref>]. This cancer is extremely genetic unstable and heterogenous; it is rarely detected while confined to the ovary and in about 90% of the cases it is diagnosed when women have already intra-abdominal spread. Although research has traditionally focused on the hypothesis that HGSC arises from the ovarian surface epithelium (OSE), it has been recently suggested that it may arise from the Fallopian tube fimbria. In particular, the serous tubal intraepithelial carcinomas (STICs), which are identified in the distal end (fimbria) of the Fallopian tube and arise from p53 mutations, have been indicated as the primary lesions that evolve through subsequent oncogenic events into HGSC [<xref rid="R3" ref-type="bibr">3</xref>]. This hypothesis is further supported by genetically engineered murine models that mimic the transformation from Fallopian tubal secretory epithelial cells to HGSC [<xref rid="R4" ref-type="bibr">4</xref>].</p><p>The transcription factor PAX8 is a marker of the Fallopian tube secretory cell lineage and its expression is retained in 96% of the serous ovarian carcinomas, in 89% of the endometrioid and 100% of the clear cell carcinomas, whilst it is not detected in the mucinous carcinoma [<xref rid="R5" ref-type="bibr">5</xref>]. PAX8 is a member of the PAX (PAired boX) gene family, genes tightly regulated in both temporal and spatial expression patterns [<xref rid="R6" ref-type="bibr">6</xref>]. PAX8 is crucial for the organogenesis of the thyroid gland, kidney, nervous system and Mullerian system [<xref rid="R7" ref-type="bibr">7</xref>, <xref rid="R8" ref-type="bibr">8</xref>]. In the adult, PAX8 is expressed in the thyroid gland, in the renal excretory system and in tissues derived from the Mullerian ducts [<xref rid="R9" ref-type="bibr">9</xref>, <xref rid="R10" ref-type="bibr">10</xref>]. Our recent results demonstrated that PAX8 plays a critical role in cell cycle progression and cell survival of differentiated epithelial cells [<xref rid="R11" ref-type="bibr">11</xref>], reinforcing the involvement of this transcription factor in different biological processes. In tumors, PAX8 is involved in the progression of follicular thyroid carcinomas [<xref rid="R12" ref-type="bibr">12</xref>] and it is overexpressed in the majority of gliomas, Wilms tumors and well-differentiated pancreatic neuroendocrine tumors [<xref rid="R10" ref-type="bibr">10</xref>, <xref rid="R13" ref-type="bibr">13</xref>, <xref rid="R14" ref-type="bibr">14</xref>]. In the scenario of ovarian cancer, PAX8 is the currently available most important marker [<xref rid="R15" ref-type="bibr">15</xref>] being a useful IHC target for the diagnosis of Mullerian tumors [<xref rid="R16" ref-type="bibr">16</xref>]. Despite PAX8 is normally expressed in Fallopian tube secretory cells, namely the cell of origin of HGSC, and is mainly considered a marker of tumor origin, we have recently reported its pivotal function in the tumorigenic phenotype of ovarian cancer cells. In particular, we showed that PAX8 plays a critical role in the migration, invasion and tumorigenic ability of ovarian cancer cells. In our published study, PAX8 silencing strongly suppressed anchorage-independent growth <italic>in vitro</italic> and significantly inhibited tumorigenesis <italic>in vivo</italic> in a nude mouse xenograft model [<xref rid="R17" ref-type="bibr">17</xref>]. In addition, the Cancer Genome Atlas (TGCA) Project indicated PAX8 as a survival gene essential for the proliferation of ovarian cancer cells [<xref rid="R5" ref-type="bibr">5</xref>]. Overall, PAX8 belongs to a class of lineage-survival genes that are required for both normal development of specific tissues and for cancer cell proliferation/survival.</p><p>On the basis of such evidences, it is conceivable that PAX8 is intimately involved in the progression of ovarian carcinomas. However, its function in Fallopian tube secretory epithelial cells, as well as the entire molecular network that allows PAX8 to regulate cellular processes in these cells and in ovarian cancer cells, is still an unexplored field. To improve our knowledge of the complex role of this transcription factor, we thought that it would be beneficial to uncover the downstream gene network governed by this transcriptional factor both in Fallopian tubal epithelium and ovarian cancer cells. Hence, the aims of our study were (1) to compare the transcriptome of normal Fallopian tube secretory epithelial cells with that of ovarian cancer cells in order to uncover genes and pathways modified during the transformation process; (2) to investigate PAX8 downstream gene regulatory network in physiological and pathological conditions to identify genes and pathways regulated by PAX8 that could be additional targets for the therapy of ovarian carcinoma.</p></sec><sec id="s2"><title>RESULTS</title><sec id="s2_1"><title>Identification of genes differentially expressed between FT194 and SKOV-3 cells</title><p>Primary questions in the field of ovarian cancer biology concern its developmental cell of origin. The epithelial cells covering the ovaries (OSE) have historically been considered the site of origin of all ovarian cancers but recent evidence suggests that high-grade serous carcinoma (HGSC) originates from the Fallopian tube (FT) epithelium or the tuboperitoneal junction rather than from the OSE [<xref rid="R4" ref-type="bibr">4</xref>, <xref rid="R18" ref-type="bibr">18</xref>].</p><p>To identify genes differentially expressed in the Fallopian tubal epithelium and in ovarian carcinoma and to disclose some of the pathways that might contribute to the carcinoma formation, an RNA sequencing analysis was performed on FT194 Fallopian tube secretory epithelial cells and SKOV-3 ovarian adenocarcinoma cells and a total of 12628 genes were mapped to the reference human genome (<xref ref-type="supplementary-material" rid="SD2">Supplementary Table S1</xref>). Of these, 7451 genes were differentially expressed in the two cell types at significant level (FDR-adjusted <italic>p</italic>-value &#x02264; 0.05) (<xref ref-type="supplementary-material" rid="SD3">Supplementary Table S2</xref>): 3553 genes resulted more expressed in SKOV-3 cells than in FT194 cells and 3778 genes were found less expressed in SKOV-3 cells with respect to FT194 cells. Interestingly, 38 genes were exclusively expressed in SKOV-3 cells, while 82 genes were present only in FT194 cells (<xref ref-type="supplementary-material" rid="SD3">Supplementary Table S2</xref>).</p><p>To date, despite the identification of a number of key mutations in p53 and BRCA1/2 genes, the complexity of the molecular pathway(s) underlying epithelial ovarian cancer has not been yet fully elucidated. To focus our attention on genes showing the greatest expression differences between FT194 and SKOV-3 cells, we applied a 2 fold-change cutoff and we searched for enrichment of specific gene sets at the Molecular Signatures Database (MsigDB). In particular, we explored the hallmark gene sets that summarize and represent specific well-defined biological states or processes. As shown in Figure <xref ref-type="fig" rid="F1">1A</xref>, genes up-regulated &#x02265; 2 fold in SKOV-3 cells present a significant enrichment for pathways such as estrogen response, epithelial mesenchymal transition, response to UV DNA damage, angiogenesis and Wnt/&#x003b2;-catenin signaling. There are numerous evidences, both <italic>in vitro</italic> and <italic>in vivo</italic> studies, that estrogens might regulate ovarian carcinogenesis [<xref rid="R19" ref-type="bibr">19</xref>]. It is well known that hormones stimulate the proliferation of the cells, meaning that they might function as carcinogens. For example, in ovarian cancer cells 17&#x003b2;-estradiol (E2) increases the ROS and NO production that participates in cancer progression [<xref rid="R20" ref-type="bibr">20</xref>]. In addition, aberrant Wnt/&#x003b2;-catenin signaling is implicated in several cancers including epithelial ovarian cancer [<xref rid="R21" ref-type="bibr">21</xref>, <xref rid="R22" ref-type="bibr">22</xref>] and it represents one of the pathway involved in epithelial-mesenchymal transition (EMT) responsible for cancer cell dissemination and metastasis formation [<xref rid="R23" ref-type="bibr">23</xref>]. Stressful conditions such as UV radiations, hypoxia, and alterations associated with changes in cell phenotype that include EMT as well as angiogenesis represent main processes that provide carcinogenesis. At the same time, genes down-regulated &#x02265; 2 fold in SKOV-3 cells (Figure <xref ref-type="fig" rid="F1">1B</xref>) are involved in pathways as TNF-&#x003b1; signaling, IFN-&#x003b1; and IFN-&#x003b3; responses and inflammatory response. TNF-&#x003b1;, IFN-&#x003b1; and IFN-&#x003b3; are pleiotropic cytokines with diverse physiological functions such as activation of macrophages, induction of immune response and apoptosis and inhibition of cell proliferation. It has been reported that in ovarian cancer the above-mentioned cytokines exert an anti-proliferative activity and induce apoptosis [<xref rid="R24" ref-type="bibr">24</xref>, <xref rid="R25" ref-type="bibr">25</xref>]. Eventually, if the immune response might contribute to the tumorigenic process, it may be also helpful in preventing the tumor properties.</p><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><title>MsigDB analysis of the most relevant genes differentially expressed between FT194 and SKOV-3 cells</title><p>(<bold>A</bold>) MsigDB for genes upregulated &#x02265; 2 fold in SKOV-3 cells. (<bold>B</bold>) MsigDB for genes downregulated &#x02265; 2 fold in SKOV-3 cells.</p></caption><graphic xlink:href="oncotarget-07-41929-g001"/></fig><p>Among the 38 genes exclusively expressed in SKOV-3 cells (<xref ref-type="supplementary-material" rid="SD3">Supplementary Table S2</xref>), ALDH1A1 [<xref rid="R26" ref-type="bibr">26</xref>], GABRA3 [<xref rid="R27" ref-type="bibr">27</xref>], FOLR1 [<xref rid="R28" ref-type="bibr">28</xref>], DPYSL5 [<xref rid="R29" ref-type="bibr">29</xref>], CGB8 [<xref rid="R30" ref-type="bibr">30</xref>], C8orf4 [<xref rid="R31" ref-type="bibr">31</xref>] and MAGEB2 [<xref rid="R32" ref-type="bibr">32</xref>] could be intriguing for the development and maintenance of the neoplastic phenotype. Similarly, among the 82 genes expressed only in FT194 cells (<xref ref-type="supplementary-material" rid="SD3">Supplementary Table S2</xref>) CDKN2A [<xref rid="R33" ref-type="bibr">33</xref>], MT1G [<xref rid="R34" ref-type="bibr">34</xref>], GPX7 [<xref rid="R35" ref-type="bibr">35</xref>], HCK [<xref rid="R36" ref-type="bibr">36</xref>], ZBTB16 [<xref rid="R37" ref-type="bibr">37</xref>] could be looked at as interesting genes being tumor suppressor epigenetically silenced in cancer cells.</p></sec><sec id="s2_2"><title>PAX8 downstream target genes in FT194 and SKOV-3 cells</title><p>As already mentioned, in the Fallopian tube epithelium the transcription factor PAX8 is a marker of the secretory cell lineage. Our RNA sequencing analysis performed on FT194 Fallopian tube secretory epithelial cells and SKOV-3 ovarian adenocarcinoma cells confirmed that PAX8 is expressed at similar levels in these two cell types (<xref ref-type="supplementary-material" rid="SD3">Supplementary Table S2</xref>), supporting the hypothesis that PAX8 is not overexpressed in epithelial ovarian carcinoma but rather that its expression is conserved from the suggested cell of origin [<xref rid="R38" ref-type="bibr">38</xref>]. Recently, we have provided the first evidence of a clear involvement of PAX8 in the <italic>in vivo</italic> tumorigenesis of ovarian cancer cells [<xref rid="R17" ref-type="bibr">17</xref>], reinforcing the role of <italic>PAX</italic> genes in cancer through their effects on apoptosis resistance, tumor cell proliferation and migration, and repression of terminal differentiation.</p><p>On the basis of our previous data and in order to clarify PAX8 contribution to ovarian cancer through the identification of its downstream gene regulatory network, we have transiently knocked-down PAX8 expression in both FT194 and SKOV-3 cells. We chose to inhibit PAX8 expression also in the FT194 cell line because to date its role in the physiological contest of the Fallopian tube secretory cell has not been investigated. Moreover, we reasoned that genes affected by PAX8 silencing in both cell lines could be looked at as PAX8 targets with greater confidence.</p><p>Three independent silencing experiments were performed and analyzed by RNA-seq unraveling a total of 467 genes modulated by PAX8 expression in SKOV-3 and FT194 cells (<xref ref-type="supplementary-material" rid="SD4">Supplementary Table S3</xref> and <xref ref-type="supplementary-material" rid="SD5">Supplementary Table S4</xref>). The reduced expression of PAX8 in the samples was confirmed by the RNA-seq findings, which showed an 80% decrease (FDR-adjusted <italic>p</italic>-value &#x02264; 0.05) (<xref ref-type="supplementary-material" rid="SD4">Supplementary Table S3</xref> and <xref ref-type="supplementary-material" rid="SD5">Supplementary Table S4</xref>).</p><p>In SKOV-3 cells, 301 genes were significantly modulated by PAX8 silencing after correction for multiple testing (FDR-adjusted <italic>p</italic>-value &#x02264; 0.05) of which 214 were downregulated while 87 resulted upregulated (<xref ref-type="supplementary-material" rid="SD4">Supplementary Table S3</xref>). As shown in Table <xref ref-type="table" rid="T1">1</xref>, among the most downregulated genes based on FDR there are <italic>TUBB2B, PPME1, ATP8A1, USP2, BLCAP, DIAPH1, FGF18</italic> and <italic>KIF12</italic>.</p><table-wrap id="T1" orientation="portrait" position="float"><label>Table 1</label><caption><title>Differentially expressed genes that are significantly modulated after PAX8 silencing in SKOV&#x02013; 3 cells</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Gene Name</th><th align="center" valign="top" rowspan="1" colspan="1">NCBI gene ID</th><th align="center" valign="top" rowspan="1" colspan="1">FPKM1</th><th align="center" valign="top" rowspan="1" colspan="1">FPKM2</th><th align="center" valign="top" rowspan="1" colspan="1">Log<sub>2</sub> fold change</th><th align="center" valign="top" rowspan="1" colspan="1">FDR <italic>q</italic> value</th><th align="center" valign="top" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">ANKRD34B</td><td align="center" valign="middle" rowspan="1" colspan="1">340120</td><td align="center" valign="middle" rowspan="1" colspan="1">0,517453</td><td align="center" valign="middle" rowspan="1" colspan="1">2,34955</td><td align="center" valign="middle" rowspan="1" colspan="1">2,18288</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">4,54059</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">PAX8</td><td align="center" valign="middle" rowspan="1" colspan="1">7849</td><td align="center" valign="middle" rowspan="1" colspan="1">8,65929</td><td align="center" valign="middle" rowspan="1" colspan="1">30,224</td><td align="center" valign="middle" rowspan="1" colspan="1">1,80338</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">3,49037</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">TUBB2B</td><td align="center" valign="middle" rowspan="1" colspan="1">347733</td><td align="center" valign="middle" rowspan="1" colspan="1">0,483395</td><td align="center" valign="middle" rowspan="1" colspan="1">1,54683</td><td align="center" valign="middle" rowspan="1" colspan="1">1,67804</td><td align="center" valign="middle" rowspan="1" colspan="1">0,015208</td><td align="center" valign="middle" rowspan="1" colspan="1">3,19993</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">PPME1</td><td align="center" valign="middle" rowspan="1" colspan="1">51400</td><td align="center" valign="middle" rowspan="1" colspan="1">11,285</td><td align="center" valign="middle" rowspan="1" colspan="1">34,0561</td><td align="center" valign="middle" rowspan="1" colspan="1">1,59351</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">3,01783</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">LMLN</td><td align="center" valign="middle" rowspan="1" colspan="1">89782</td><td align="center" valign="middle" rowspan="1" colspan="1">0,558739</td><td align="center" valign="middle" rowspan="1" colspan="1">1,61854</td><td align="center" valign="middle" rowspan="1" colspan="1">1,53445</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,89678</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">H2AFY2</td><td align="center" valign="middle" rowspan="1" colspan="1">55506</td><td align="center" valign="middle" rowspan="1" colspan="1">6,68489</td><td align="center" valign="middle" rowspan="1" colspan="1">19,0865</td><td align="center" valign="middle" rowspan="1" colspan="1">1,51358</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,85518</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">PHTF2</td><td align="center" valign="middle" rowspan="1" colspan="1">57157</td><td align="center" valign="middle" rowspan="1" colspan="1">3,23708</td><td align="center" valign="middle" rowspan="1" colspan="1">8,76508</td><td align="center" valign="middle" rowspan="1" colspan="1">1,43707</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,70770</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">DCAF12L1</td><td align="center" valign="middle" rowspan="1" colspan="1">139170</td><td align="center" valign="middle" rowspan="1" colspan="1">1,66899</td><td align="center" valign="middle" rowspan="1" colspan="1">4,506</td><td align="center" valign="middle" rowspan="1" colspan="1">1,43287</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,69983</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">GRIN2B</td><td align="center" valign="middle" rowspan="1" colspan="1">2904</td><td align="center" valign="middle" rowspan="1" colspan="1">0,727982</td><td align="center" valign="middle" rowspan="1" colspan="1">1,94915</td><td align="center" valign="middle" rowspan="1" colspan="1">1,42087</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0100329</td><td align="center" valign="middle" rowspan="1" colspan="1">2,67747</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">EPRS</td><td align="center" valign="middle" rowspan="1" colspan="1">2058</td><td align="center" valign="middle" rowspan="1" colspan="1">18,5003</td><td align="center" valign="middle" rowspan="1" colspan="1">47,5384</td><td align="center" valign="middle" rowspan="1" colspan="1">1,36154</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,56959</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">PPAP2B</td><td align="center" valign="middle" rowspan="1" colspan="1">8613</td><td align="center" valign="middle" rowspan="1" colspan="1">5,23887</td><td align="center" valign="middle" rowspan="1" colspan="1">13,3333</td><td align="center" valign="middle" rowspan="1" colspan="1">1,3477</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,54506</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">ATP8A1</td><td align="center" valign="middle" rowspan="1" colspan="1">10396</td><td align="center" valign="middle" rowspan="1" colspan="1">0,686376</td><td align="center" valign="middle" rowspan="1" colspan="1">1,74582</td><td align="center" valign="middle" rowspan="1" colspan="1">1,34683</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,54353</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">USP2</td><td align="center" valign="middle" rowspan="1" colspan="1">9099</td><td align="center" valign="middle" rowspan="1" colspan="1">0,582276</td><td align="center" valign="middle" rowspan="1" colspan="1">1,43193</td><td align="center" valign="middle" rowspan="1" colspan="1">1,29819</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0127719</td><td align="center" valign="middle" rowspan="1" colspan="1">2,45920</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">BLCAP</td><td align="center" valign="middle" rowspan="1" colspan="1">10904</td><td align="center" valign="middle" rowspan="1" colspan="1">9,66632</td><td align="center" valign="middle" rowspan="1" colspan="1">23,4671</td><td align="center" valign="middle" rowspan="1" colspan="1">1,2796</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,42771</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">FGF18</td><td align="center" valign="middle" rowspan="1" colspan="1">8817</td><td align="center" valign="middle" rowspan="1" colspan="1">2,82984</td><td align="center" valign="middle" rowspan="1" colspan="1">6,85593</td><td align="center" valign="middle" rowspan="1" colspan="1">1,27663</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,42272</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">DIAPH1</td><td align="center" valign="middle" rowspan="1" colspan="1">1729</td><td align="center" valign="middle" rowspan="1" colspan="1">5,21853</td><td align="center" valign="middle" rowspan="1" colspan="1">12,5088</td><td align="center" valign="middle" rowspan="1" colspan="1">1,26123</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,39700</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">KIF12</td><td align="center" valign="middle" rowspan="1" colspan="1">113220</td><td align="center" valign="middle" rowspan="1" colspan="1">2,32013</td><td align="center" valign="middle" rowspan="1" colspan="1">5,50046</td><td align="center" valign="middle" rowspan="1" colspan="1">1,24535</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,37076</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">C10orf46</td><td align="center" valign="middle" rowspan="1" colspan="1">143384</td><td align="center" valign="middle" rowspan="1" colspan="1">14,0943</td><td align="center" valign="middle" rowspan="1" colspan="1">33,1881</td><td align="center" valign="middle" rowspan="1" colspan="1">1,23555</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,35471</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">ANXA2P2</td><td align="center" valign="middle" rowspan="1" colspan="1">304</td><td align="center" valign="middle" rowspan="1" colspan="1">1,92906</td><td align="center" valign="middle" rowspan="1" colspan="1">4,516</td><td align="center" valign="middle" rowspan="1" colspan="1">1,22715</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,34104</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">PSAP</td><td align="center" valign="middle" rowspan="1" colspan="1">5660</td><td align="center" valign="middle" rowspan="1" colspan="1">201,624</td><td align="center" valign="middle" rowspan="1" colspan="1">467,609</td><td align="center" valign="middle" rowspan="1" colspan="1">1,21364</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,31922</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">DIO2</td><td align="center" valign="middle" rowspan="1" colspan="1">1734</td><td align="center" valign="middle" rowspan="1" colspan="1">5,30475</td><td align="center" valign="middle" rowspan="1" colspan="1">1,69721</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,64412</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">3,12557</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">ROS1</td><td align="center" valign="middle" rowspan="1" colspan="1">6098</td><td align="center" valign="middle" rowspan="1" colspan="1">2,97713</td><td align="center" valign="middle" rowspan="1" colspan="1">1,06039</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,48933</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,80759</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">P4HA3</td><td align="center" valign="middle" rowspan="1" colspan="1">283208</td><td align="center" valign="middle" rowspan="1" colspan="1">1,91889</td><td align="center" valign="middle" rowspan="1" colspan="1">0,746284</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,36248</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,57127</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">PTPMT1</td><td align="center" valign="middle" rowspan="1" colspan="1">114971</td><td align="center" valign="middle" rowspan="1" colspan="1">14,4328</td><td align="center" valign="middle" rowspan="1" colspan="1">5,88494</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,29426</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0196014</td><td align="center" valign="middle" rowspan="1" colspan="1">2,45251</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">MET</td><td align="center" valign="middle" rowspan="1" colspan="1">4233</td><td align="center" valign="middle" rowspan="1" colspan="1">47,8695</td><td align="center" valign="middle" rowspan="1" colspan="1">20,5651</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,21891</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,32771</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">CCIN</td><td align="center" valign="middle" rowspan="1" colspan="1">881</td><td align="center" valign="middle" rowspan="1" colspan="1">1,24831</td><td align="center" valign="middle" rowspan="1" colspan="1">0,566005</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,14109</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0361254</td><td align="center" valign="middle" rowspan="1" colspan="1">2,20548</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">ARTN</td><td align="center" valign="middle" rowspan="1" colspan="1">9048</td><td align="center" valign="middle" rowspan="1" colspan="1">5,77216</td><td align="center" valign="middle" rowspan="1" colspan="1">2,63816</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,12958</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,18795</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">LOC100507412</td><td align="center" valign="middle" rowspan="1" colspan="1">100507412</td><td align="center" valign="middle" rowspan="1" colspan="1">394,087</td><td align="center" valign="middle" rowspan="1" colspan="1">186,2</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,08166</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,11647</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">SERPINB5</td><td align="center" valign="middle" rowspan="1" colspan="1">5268</td><td align="center" valign="middle" rowspan="1" colspan="1">1,49223</td><td align="center" valign="middle" rowspan="1" colspan="1">0,722489</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,04642</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0340659</td><td align="center" valign="middle" rowspan="1" colspan="1">2,06540</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">SERPINE1</td><td align="center" valign="middle" rowspan="1" colspan="1">5054</td><td align="center" valign="middle" rowspan="1" colspan="1">128,607</td><td align="center" valign="middle" rowspan="1" colspan="1">62,4787</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,04153</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,05841</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">DKK1</td><td align="center" valign="middle" rowspan="1" colspan="1">22943</td><td align="center" valign="middle" rowspan="1" colspan="1">85,9562</td><td align="center" valign="middle" rowspan="1" colspan="1">42,0833</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,03035</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,04252</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">SGK1</td><td align="center" valign="middle" rowspan="1" colspan="1">6446</td><td align="center" valign="middle" rowspan="1" colspan="1">18,4838</td><td align="center" valign="middle" rowspan="1" colspan="1">9,10546</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,02146</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">2,02997</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">FGF1</td><td align="center" valign="middle" rowspan="1" colspan="1">2246</td><td align="center" valign="middle" rowspan="1" colspan="1">1,67617</td><td align="center" valign="middle" rowspan="1" colspan="1">0,843698</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,990371</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">1,98670</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">BOD1</td><td align="center" valign="middle" rowspan="1" colspan="1">91272</td><td align="center" valign="middle" rowspan="1" colspan="1">27,4212</td><td align="center" valign="middle" rowspan="1" colspan="1">14,2379</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,945548</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">1,92592</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">CCND3</td><td align="center" valign="middle" rowspan="1" colspan="1">896</td><td align="center" valign="middle" rowspan="1" colspan="1">27,6423</td><td align="center" valign="middle" rowspan="1" colspan="1">14,3971</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,941101</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">1,91999</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">TGFB2</td><td align="center" valign="middle" rowspan="1" colspan="1">7042</td><td align="center" valign="middle" rowspan="1" colspan="1">13,4826</td><td align="center" valign="middle" rowspan="1" colspan="1">7,11507</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,922151</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">1,89494</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td align="center" valign="middle" rowspan="1" colspan="1">CALU</td><td align="center" valign="middle" rowspan="1" colspan="1">813</td><td align="center" valign="middle" rowspan="1" colspan="1">57,1015</td><td align="center" valign="middle" rowspan="1" colspan="1">30,1837</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,919757</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">1,89180</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">ANKRD1</td><td align="center" valign="middle" rowspan="1" colspan="1">27063</td><td align="center" valign="middle" rowspan="1" colspan="1">10,4157</td><td align="center" valign="middle" rowspan="1" colspan="1">5,56174</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,905149</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">1,87274</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">CGB8</td><td align="center" valign="middle" rowspan="1" colspan="1">94115</td><td align="center" valign="middle" rowspan="1" colspan="1">11,0552</td><td align="center" valign="middle" rowspan="1" colspan="1">5,93536</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,897321</td><td align="center" valign="middle" rowspan="1" colspan="1">0,015208</td><td align="center" valign="middle" rowspan="1" colspan="1">1,86260</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">C6orf120</td><td align="center" valign="middle" rowspan="1" colspan="1">387263</td><td align="center" valign="middle" rowspan="1" colspan="1">18,0817</td><td align="center" valign="middle" rowspan="1" colspan="1">9,71162</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,896746</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00400937</td><td align="center" valign="middle" rowspan="1" colspan="1">1,86186</td></tr></tbody></table><table-wrap-foot><p>Note: FPKM1 and FPKM2 indicate fragments per kilobase of exon per million mapped reads after and before PAX8 silencing, respectively. Genes from 1 to 20 are downregulated and genes from 21 to 40 are upregulated.</p></table-wrap-foot></table-wrap><p><italic>TUBB2B</italic> (tubulin beta 2B class IIb) may have important roles in tumor progression and chemoresistance [<xref rid="R39" ref-type="bibr">39</xref>]. <italic>PPME1</italic> is a protein phosphatase 2A (PP2A)-specific methylesterase that mediates the demethylation and inactivation of PP2A. This protein is a human tumor suppressor that accounts for the majority of cellular serine/threonine phosphatase activity [<xref rid="R40" ref-type="bibr">40</xref>]. <italic>ATP8A1</italic> is a member of P4-ATPase family with a role in the formation of membrane ruffles to promote cell migration [<xref rid="R41" ref-type="bibr">41</xref>]. <italic>BLPAP</italic> (Bladder cancer-associated protein) is a highly conserved protein among species displaying tissue-specific expression patterns, but also tissue-specific functions being both a tumor suppressor and a tumor promoting [<xref rid="R42" ref-type="bibr">42</xref>]. Recent data revealed that the blockade of DIAPH1-tubulin interaction might be a promising approach to inhibit one of the earliest steps in the metastatic cascade of colon cancer [<xref rid="R43" ref-type="bibr">43</xref>]. <italic>FGF18</italic> is a pleiotropic growth factor involved in skeletal growth and development [<xref rid="R44" ref-type="bibr">44</xref>, <xref rid="R45" ref-type="bibr">45</xref>]. Deregulated FGF signaling may affect some oncogenic mechanisms and properties in various tumor types [<xref rid="R46" ref-type="bibr">46</xref>]. <italic>KIF12</italic> belongs to the kinesin superfamily of motor proteins that bind microtubules and mediate the intracellular transport of organelles and protein complexes [<xref rid="R47" ref-type="bibr">47</xref>].</p><p>Interestingly, in siPAX8-SKOV-3 cells among the most up-regulated genes based on FDR there are <italic>DKK1</italic> and <italic>BOD-1</italic> [<xref rid="R48" ref-type="bibr">48</xref>] (Table <xref ref-type="table" rid="T1">1</xref>). DKK1 belongs to the <italic>Dickkopf</italic> gene family, which encodes secreted glycoproteins to control cell fate and neural patterning during embryonic development. It was first identified as an inhibitor of the Wnt signaling pathway. <italic>BOD-1</italic> is a member of the FAM44 protein family and is highly conserved throughout metazoans. Depletion of <italic>BOD-1</italic> in human cells causes severe biorientation defects [<xref rid="R49" ref-type="bibr">49</xref>].</p><p>In FT194 cells, 166 genes affected by PAX8 silencing reached genome-wide significance after correction for multiple testing (FDR-adjusted <italic>p</italic>-value &#x02264; 0.05) of which 119 were downregulated while 47 were upregulated (<xref ref-type="supplementary-material" rid="SD5">Supplementary Table S4</xref>). Among the most significantly downregulated genes there are: <italic>FGF18, CDH6, CHRD, ZBED2, CNTN4, ANXA2</italic> (Table <xref ref-type="table" rid="T2">2</xref>). Very interestingly, <italic>FGF18</italic> results among the top 20 downregulated genes upon silencing of PAX8 in both SKOV-3 and in FT194 cells (Table <xref ref-type="table" rid="T1">1</xref> and Table <xref ref-type="table" rid="T2">2</xref>).</p><table-wrap id="T2" orientation="portrait" position="float"><label>Table 2</label><caption><title>Differentially expressed genes that are significantly modulated after PAX8 silencing in FT194 cells</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="top" rowspan="1" colspan="1"/><th align="center" valign="top" rowspan="1" colspan="1">Gene Name</th><th align="center" valign="top" rowspan="1" colspan="1">NCBI gene ID</th><th align="center" valign="top" rowspan="1" colspan="1">FPKM1</th><th align="center" valign="top" rowspan="1" colspan="1">FPKM2</th><th align="center" valign="top" rowspan="1" colspan="1">Log<sub>2</sub> fold change</th><th align="center" valign="top" rowspan="1" colspan="1">FDR <italic>q</italic> value</th><th align="center" valign="top" rowspan="1" colspan="1">Fold change</th></tr></thead><tbody><tr><td align="center" valign="middle" rowspan="1" colspan="1">1</td><td align="center" valign="middle" rowspan="1" colspan="1">CDH6</td><td align="center" valign="middle" rowspan="1" colspan="1">1004</td><td align="center" valign="middle" rowspan="1" colspan="1">0,904512</td><td align="center" valign="middle" rowspan="1" colspan="1">5,66947</td><td align="center" valign="middle" rowspan="1" colspan="1">2,648</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">6,26798</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">2</td><td align="center" valign="middle" rowspan="1" colspan="1">SNORA26</td><td align="center" valign="middle" rowspan="1" colspan="1">677810</td><td align="center" valign="middle" rowspan="1" colspan="1">12,5059</td><td align="center" valign="middle" rowspan="1" colspan="1">73,4428</td><td align="center" valign="middle" rowspan="1" colspan="1">2,55401</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">5,87264</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">3</td><td align="center" valign="middle" rowspan="1" colspan="1">FGF18</td><td align="center" valign="middle" rowspan="1" colspan="1">8817</td><td align="center" valign="middle" rowspan="1" colspan="1">2,9921</td><td align="center" valign="middle" rowspan="1" colspan="1">14,7197</td><td align="center" valign="middle" rowspan="1" colspan="1">2,29852</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">4,91953</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">4</td><td align="center" valign="middle" rowspan="1" colspan="1">CHRD</td><td align="center" valign="middle" rowspan="1" colspan="1">8646</td><td align="center" valign="middle" rowspan="1" colspan="1">1,14353</td><td align="center" valign="middle" rowspan="1" colspan="1">5,39776</td><td align="center" valign="middle" rowspan="1" colspan="1">2,23887</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">4,72027</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">5</td><td align="center" valign="middle" rowspan="1" colspan="1">KLHL14</td><td align="center" valign="middle" rowspan="1" colspan="1">57565</td><td align="center" valign="middle" rowspan="1" colspan="1">0,218892</td><td align="center" valign="middle" rowspan="1" colspan="1">0,999955</td><td align="center" valign="middle" rowspan="1" colspan="1">2,19164</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">4,56824</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">6</td><td align="center" valign="middle" rowspan="1" colspan="1">EPHB1</td><td align="center" valign="middle" rowspan="1" colspan="1">2047</td><td align="center" valign="middle" rowspan="1" colspan="1">0,17794</td><td align="center" valign="middle" rowspan="1" colspan="1">0,77373</td><td align="center" valign="middle" rowspan="1" colspan="1">2,12044</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0162802</td><td align="center" valign="middle" rowspan="1" colspan="1">4,34827</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">7</td><td align="center" valign="middle" rowspan="1" colspan="1">ZBED2</td><td align="center" valign="middle" rowspan="1" colspan="1">79413</td><td align="center" valign="middle" rowspan="1" colspan="1">0,98563</td><td align="center" valign="middle" rowspan="1" colspan="1">4,13057</td><td align="center" valign="middle" rowspan="1" colspan="1">2,06722</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">4,19078</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">8</td><td align="center" valign="middle" rowspan="1" colspan="1">TLL2</td><td align="center" valign="middle" rowspan="1" colspan="1">7093</td><td align="center" valign="middle" rowspan="1" colspan="1">0,625627</td><td align="center" valign="middle" rowspan="1" colspan="1">2,60957</td><td align="center" valign="middle" rowspan="1" colspan="1">2,06043</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">4,17111</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">9</td><td align="center" valign="middle" rowspan="1" colspan="1">PAX8</td><td align="center" valign="middle" rowspan="1" colspan="1">7849</td><td align="center" valign="middle" rowspan="1" colspan="1">9,23106</td><td align="center" valign="middle" rowspan="1" colspan="1">33,8269</td><td align="center" valign="middle" rowspan="1" colspan="1">1,8736</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,66446</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">10</td><td align="center" valign="middle" rowspan="1" colspan="1">BAALC</td><td align="center" valign="middle" rowspan="1" colspan="1">79870</td><td align="center" valign="middle" rowspan="1" colspan="1">0,360111</td><td align="center" valign="middle" rowspan="1" colspan="1">1,28504</td><td align="center" valign="middle" rowspan="1" colspan="1">1,8353</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0333357</td><td align="center" valign="middle" rowspan="1" colspan="1">3,56846</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">11</td><td align="center" valign="middle" rowspan="1" colspan="1">MAL</td><td align="center" valign="middle" rowspan="1" colspan="1">4118</td><td align="center" valign="middle" rowspan="1" colspan="1">7,14709</td><td align="center" valign="middle" rowspan="1" colspan="1">25,0391</td><td align="center" valign="middle" rowspan="1" colspan="1">1,80876</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,50341</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">12</td><td align="center" valign="middle" rowspan="1" colspan="1">DCDC2</td><td align="center" valign="middle" rowspan="1" colspan="1">51473</td><td align="center" valign="middle" rowspan="1" colspan="1">4,33336</td><td align="center" valign="middle" rowspan="1" colspan="1">14,9979</td><td align="center" valign="middle" rowspan="1" colspan="1">1,7912</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,46103</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">13</td><td align="center" valign="middle" rowspan="1" colspan="1">LOC643201</td><td align="center" valign="middle" rowspan="1" colspan="1">643201</td><td align="center" valign="middle" rowspan="1" colspan="1">1,32389</td><td align="center" valign="middle" rowspan="1" colspan="1">4,51658</td><td align="center" valign="middle" rowspan="1" colspan="1">1,77045</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,41160</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">14</td><td align="center" valign="middle" rowspan="1" colspan="1">ADAMTS14</td><td align="center" valign="middle" rowspan="1" colspan="1">140766</td><td align="center" valign="middle" rowspan="1" colspan="1">0,900768</td><td align="center" valign="middle" rowspan="1" colspan="1">3,0108</td><td align="center" valign="middle" rowspan="1" colspan="1">1,74092</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,34248</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">15</td><td align="center" valign="middle" rowspan="1" colspan="1">CNTN4</td><td align="center" valign="middle" rowspan="1" colspan="1">152330</td><td align="center" valign="middle" rowspan="1" colspan="1">0,800182</td><td align="center" valign="middle" rowspan="1" colspan="1">2,67321</td><td align="center" valign="middle" rowspan="1" colspan="1">1,74017</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,34075</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">16</td><td align="center" valign="middle" rowspan="1" colspan="1">ANXA2</td><td align="center" valign="middle" rowspan="1" colspan="1">302</td><td align="center" valign="middle" rowspan="1" colspan="1">572,227</td><td align="center" valign="middle" rowspan="1" colspan="1">1838,55</td><td align="center" valign="middle" rowspan="1" colspan="1">1,68391</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,21298</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">17</td><td align="center" valign="middle" rowspan="1" colspan="1">FAT2</td><td align="center" valign="middle" rowspan="1" colspan="1">2196</td><td align="center" valign="middle" rowspan="1" colspan="1">0,373409</td><td align="center" valign="middle" rowspan="1" colspan="1">1,18513</td><td align="center" valign="middle" rowspan="1" colspan="1">1,66622</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,17382</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">18</td><td align="center" valign="middle" rowspan="1" colspan="1">ANXA2P2</td><td align="center" valign="middle" rowspan="1" colspan="1">304</td><td align="center" valign="middle" rowspan="1" colspan="1">1,12435</td><td align="center" valign="middle" rowspan="1" colspan="1">3,55187</td><td align="center" valign="middle" rowspan="1" colspan="1">1,65948</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0115711</td><td align="center" valign="middle" rowspan="1" colspan="1">3,15903</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">19</td><td align="center" valign="middle" rowspan="1" colspan="1">ROR1</td><td align="center" valign="middle" rowspan="1" colspan="1">4919</td><td align="center" valign="middle" rowspan="1" colspan="1">7,26579</td><td align="center" valign="middle" rowspan="1" colspan="1">22,3551</td><td align="center" valign="middle" rowspan="1" colspan="1">1,62141</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">3,07676</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">20</td><td align="center" valign="middle" rowspan="1" colspan="1">LMLN</td><td align="center" valign="middle" rowspan="1" colspan="1">89782</td><td align="center" valign="middle" rowspan="1" colspan="1">0,291647</td><td align="center" valign="middle" rowspan="1" colspan="1">0,876636</td><td align="center" valign="middle" rowspan="1" colspan="1">1,58775</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0115711</td><td align="center" valign="middle" rowspan="1" colspan="1">3,00580</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">21</td><td align="center" valign="middle" rowspan="1" colspan="1">SERPINB2</td><td align="center" valign="middle" rowspan="1" colspan="1">5055</td><td align="center" valign="middle" rowspan="1" colspan="1">4,52656</td><td align="center" valign="middle" rowspan="1" colspan="1">1,12888</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 2,00352</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">4,00977</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">22</td><td align="center" valign="middle" rowspan="1" colspan="1">FPR1</td><td align="center" valign="middle" rowspan="1" colspan="1">2357</td><td align="center" valign="middle" rowspan="1" colspan="1">18,91</td><td align="center" valign="middle" rowspan="1" colspan="1">7,18704</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,39568</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">2,63113</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">23</td><td align="center" valign="middle" rowspan="1" colspan="1">PAPPA</td><td align="center" valign="middle" rowspan="1" colspan="1">5069</td><td align="center" valign="middle" rowspan="1" colspan="1">4,39506</td><td align="center" valign="middle" rowspan="1" colspan="1">1,94254</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,17794</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">2,26253</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">24</td><td align="center" valign="middle" rowspan="1" colspan="1">PTGS2</td><td align="center" valign="middle" rowspan="1" colspan="1">5743</td><td align="center" valign="middle" rowspan="1" colspan="1">14,4361</td><td align="center" valign="middle" rowspan="1" colspan="1">6,46952</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,15795</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">2,23140</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">25</td><td align="center" valign="middle" rowspan="1" colspan="1">NRK</td><td align="center" valign="middle" rowspan="1" colspan="1">203447</td><td align="center" valign="middle" rowspan="1" colspan="1">2,78453</td><td align="center" valign="middle" rowspan="1" colspan="1">1,25142</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,15387</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">2,22510</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">26</td><td align="center" valign="middle" rowspan="1" colspan="1">ST6GALNAC5</td><td align="center" valign="middle" rowspan="1" colspan="1">81849</td><td align="center" valign="middle" rowspan="1" colspan="1">10,3815</td><td align="center" valign="middle" rowspan="1" colspan="1">4,81544</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,10827</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">2,15587</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">27</td><td align="center" valign="middle" rowspan="1" colspan="1">THBD</td><td align="center" valign="middle" rowspan="1" colspan="1">7056</td><td align="center" valign="middle" rowspan="1" colspan="1">7,82686</td><td align="center" valign="middle" rowspan="1" colspan="1">3,66541</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 1,09446</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">2,13533</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">28</td><td align="center" valign="middle" rowspan="1" colspan="1">CCL20</td><td align="center" valign="middle" rowspan="1" colspan="1">6364</td><td align="center" valign="middle" rowspan="1" colspan="1">60,3995</td><td align="center" valign="middle" rowspan="1" colspan="1">30,2135</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,999342</td><td align="center" valign="middle" rowspan="1" colspan="1">0,0162802</td><td align="center" valign="middle" rowspan="1" colspan="1">1,99909</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">29</td><td align="center" valign="middle" rowspan="1" colspan="1">RHOB</td><td align="center" valign="middle" rowspan="1" colspan="1">388</td><td align="center" valign="middle" rowspan="1" colspan="1">44,0161</td><td align="center" valign="middle" rowspan="1" colspan="1">22,2603</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,983562</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,97734</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">30</td><td align="center" valign="middle" rowspan="1" colspan="1">F3</td><td align="center" valign="middle" rowspan="1" colspan="1">2152</td><td align="center" valign="middle" rowspan="1" colspan="1">132,89</td><td align="center" valign="middle" rowspan="1" colspan="1">67,4915</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,977451</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,96898</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">31</td><td align="center" valign="middle" rowspan="1" colspan="1">TGFB2</td><td align="center" valign="middle" rowspan="1" colspan="1">7042</td><td align="center" valign="middle" rowspan="1" colspan="1">53,4068</td><td align="center" valign="middle" rowspan="1" colspan="1">27,4917</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,958027</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,94265</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">32</td><td align="center" valign="middle" rowspan="1" colspan="1">ZCCHC2</td><td align="center" valign="middle" rowspan="1" colspan="1">54877</td><td align="center" valign="middle" rowspan="1" colspan="1">9,21038</td><td align="center" valign="middle" rowspan="1" colspan="1">4,7504</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,955212</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,93886</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">33</td><td align="center" valign="middle" rowspan="1" colspan="1">DCN</td><td align="center" valign="middle" rowspan="1" colspan="1">1634</td><td align="center" valign="middle" rowspan="1" colspan="1">20,2125</td><td align="center" valign="middle" rowspan="1" colspan="1">10,5292</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,940855</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,91967</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">34</td><td align="center" valign="middle" rowspan="1" colspan="1">MX2</td><td align="center" valign="middle" rowspan="1" colspan="1">4600</td><td align="center" valign="middle" rowspan="1" colspan="1">66,0911</td><td align="center" valign="middle" rowspan="1" colspan="1">34,8487</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,923353</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,89652</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">35</td><td align="center" valign="middle" rowspan="1" colspan="1">RSAD2</td><td align="center" valign="middle" rowspan="1" colspan="1">91543</td><td align="center" valign="middle" rowspan="1" colspan="1">72,3042</td><td align="center" valign="middle" rowspan="1" colspan="1">38,7711</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,899096</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,86490</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">36</td><td align="center" valign="middle" rowspan="1" colspan="1">MSRB3</td><td align="center" valign="middle" rowspan="1" colspan="1">253827</td><td align="center" valign="middle" rowspan="1" colspan="1">35,8124</td><td align="center" valign="middle" rowspan="1" colspan="1">19,2352</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,896709</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,86181</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">37</td><td align="center" valign="middle" rowspan="1" colspan="1">MET</td><td align="center" valign="middle" rowspan="1" colspan="1">4233</td><td align="center" valign="middle" rowspan="1" colspan="1">54,6992</td><td align="center" valign="middle" rowspan="1" colspan="1">30,1665</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,858572</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,81324</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">38</td><td align="center" valign="middle" rowspan="1" colspan="1">MX1</td><td align="center" valign="middle" rowspan="1" colspan="1">4599</td><td align="center" valign="middle" rowspan="1" colspan="1">264,614</td><td align="center" valign="middle" rowspan="1" colspan="1">148,11</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,837216</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,78660</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">39</td><td align="center" valign="middle" rowspan="1" colspan="1">CYP1B1</td><td align="center" valign="middle" rowspan="1" colspan="1">1545</td><td align="center" valign="middle" rowspan="1" colspan="1">64,4002</td><td align="center" valign="middle" rowspan="1" colspan="1">36,0841</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,835702</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,78473</td></tr><tr><td align="center" valign="middle" rowspan="1" colspan="1">40</td><td align="center" valign="middle" rowspan="1" colspan="1">NCOA7</td><td align="center" valign="middle" rowspan="1" colspan="1">135112</td><td align="center" valign="middle" rowspan="1" colspan="1">27,7387</td><td align="center" valign="middle" rowspan="1" colspan="1">15,6627</td><td align="center" valign="middle" rowspan="1" colspan="1">&#x02013; 0,824561</td><td align="center" valign="middle" rowspan="1" colspan="1">0,00642248</td><td align="center" valign="middle" rowspan="1" colspan="1">1,77100</td></tr></tbody></table><table-wrap-foot><p>Note: FPKM1 and FPKM2 indicate fragments per kilobase of exon per million mapped reads after and before PAX8 silencing, respectively. Genes from 1 to 20 were downregulated and genes from 21 to 40 were upregulated.</p></table-wrap-foot></table-wrap><p><italic>CDH6</italic>, a member of the cadherin superfamily, is required for the kidney development as well as ganglia formation [<xref rid="R50" ref-type="bibr">50</xref>, <xref rid="R51" ref-type="bibr">51</xref>]. Increased expression of this gene may be associated with tumor growth and metastasis [<xref rid="R52" ref-type="bibr">52</xref>]. <italic>CHRD</italic> functions as a dorsalizing factor for early vertebrate embryonic tissues by binding to ventralizing TGF-beta family bone morphogenetic proteins (BMPs) and sequestering them in latent complexes [<xref rid="R53" ref-type="bibr">53</xref>]. <italic>ZBED2</italic> (Zinc Finger, BED-Type Containing 2) is a member of family factors involved in the regulation of various functions in vertebrates [<xref rid="R54" ref-type="bibr">54</xref>]. <italic>CNTN4</italic> is a glycosylphosphatidylinositol (GPI)-anchored neuronal membrane protein responsible for the formation of axon connections in the developing nervous system [<xref rid="R55" ref-type="bibr">55</xref>]. Loss of heterozygosity (LOH) and gene sequencing analysis investigate the possibility of CNTN4 to function as tumor suppressor gene in ovarian cancer [<xref rid="R56" ref-type="bibr">56</xref>]. <italic>ANXA2</italic> is a calcium-binding cytoskeletal protein aberrantly expressed in a wide spectrum of cancers and in EOC may promote cell proliferation [<xref rid="R57" ref-type="bibr">57</xref>].</p><p>Additionally, in siPAX8-FT194 cells among the top 20 significantly upregulated genes there are: <italic>SERPINB2, FPR1, PAPPA, CCL20, RHOB, DCN</italic> (Table <xref ref-type="table" rid="T2">2</xref>).</p><p><italic>SERPINB2</italic>, also named Plasminogen Activator Inhibitor, Type II (PAI-2) is upregulated by numerous inflammatory conditions [<xref rid="R58" ref-type="bibr">58</xref>]; in cancer disease its expression is often an indicator of positive prognosis as described in ovarian cancer [<xref rid="R59" ref-type="bibr">59</xref>, <xref rid="R60" ref-type="bibr">60</xref>]. <italic>FPR1</italic> is a G protein-coupled receptor that promotes growth, angiogenesis and invasion in glioblastoma tumor [<xref rid="R61" ref-type="bibr">61</xref>]. FPR1 as the other two FPRs play a pivotal role in inflammatory response, tissue repair, tumor growth, physiological and pathological angiogenesis [<xref rid="R62" ref-type="bibr">62</xref>]. <italic>PAPPA</italic> (pregnancy-associated plasma protein A) regulates mitotic progression through modulating the IGF1 signaling pathway [<xref rid="R63" ref-type="bibr">63</xref>]. <italic>CCL20</italic> is a small cytokine constitutively produced by Fallopian tube epithelial cells and able to function as endogenous anti-viral microbicide of female reproductive tract [<xref rid="R64" ref-type="bibr">64</xref>]. In ovarian cancer, CCL20 is one of the primary chemokine induced via NF-kB pathway [<xref rid="R65" ref-type="bibr">65</xref>]. <italic>RHOB</italic>, is a member of small GTPases belonging to the Ras protein superfamily, might have a suppressive activity in cancer progression, in fact its loss occurs frequently in ovary carcinogenesis and progression. Moreover, ectopic expression of RhoB into nude mice is highly effective in suppressing tumor growth of ovarian cancer xenografts [<xref rid="R66" ref-type="bibr">66</xref>]. <italic>DCN</italic> is a small leucine-rich proteoglycan, component of connective tissue responsible for the matrix assembly. Also this factor might function as a tumor suppressor in ovarian cancer, because its expression is lost during epithelial transformation [<xref rid="R67" ref-type="bibr">67</xref>].</p></sec><sec id="s2_3"><title>PAX8 regulates the expression of shared and exclusive sets of genes in SKOV-3 and FT194 cells</title><p>As illustrated in the above paragraph, following PAX8 silencing 214 downregulated and 87 upregulated genes were identified in siPAX8-SKOV-3 cells while 119 downregulated and 47 up-regulated were defined in siPAX8-FT194 cells (FDR-adjusted <italic>p</italic>-value &#x02264; 0.05) (<xref ref-type="supplementary-material" rid="SD4">Supplementary Table S3</xref> and <xref ref-type="supplementary-material" rid="SD5">Supplementary Table S4</xref>). A Venn diagram was constructed to identify shared and distinct sets of genes regulated by PAX8 in the two cell types. As shown in Figure <xref ref-type="fig" rid="F2">2A</xref>, 47 genes are commonly downregulated in siPAX8-SKOV-3 and siPAX8-FT194 cells, whereas the genes downregulated only in one of the samples are 167 and 72 (SKOV-3 and FT194, respectively). Analogously, 15 genes are commonly upregulated in siPAX8-SKOV-3 and siPAX8-FT194 cells while 72 and 32 genes are exclusively upregulated in SKOV-3 and FT194 cells, respectively (Figure <xref ref-type="fig" rid="F2">2B</xref>). The complete lists of the genes classified according to the Venn diagram are shown in Table <xref ref-type="table" rid="T3">3</xref>.</p><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><title>The Venn diagram of genes modulated upon PAX8 knockdown in SKOV-3 and FT194 cells</title><p>(<bold>A</bold>) Overlap and differences of downregulated genes following PAX8 silencing between SKOV-3 and FT194 cells. (<bold>B</bold>) Overlap and differences of upregulated genes following PAX8 silencing between SKOV-3 and FT194 cells.</p></caption><graphic xlink:href="oncotarget-07-41929-g002"/></fig><table-wrap-group id="T3" orientation="portrait" position="float"><table-wrap orientation="portrait" id="d35e2109" position="anchor"><label>Table 3A</label><caption><title>List of shared and exclusive genes downregulated upon PAX8 silencing in SKOV-3 and FT194 cells</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" rowspan="1" colspan="1">Elements</th></tr></thead><tbody><tr><td align="center" valign="top" rowspan="1" colspan="1">SKOV3-FT194</td><td align="center" valign="top" rowspan="1" colspan="1">47</td><td align="left" valign="top" rowspan="1" colspan="1">NUP35 ANXA2 HDGFRP3 STX3 DUSP11 AP1G1 ENPP4 PHLDA3 PSAP ENPP1 EPRS RHPN2 C10orf46 GPR63 CDK2AP1 H2AFY2 PPME1 LMLN KITLG CDH6<xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref>FAM107B C1orf186 BLCAP TEX30 LONRF1 DIAPH1 FGF18<xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref> TCN2 ROR1 AKR1B1 TGOLN2 KAZN PHTF2 ARL4C MAL ADCY9 PPAP2B PAX8<xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref> ARL5A MAL2 MRE11A HTATSF1 GPR56 PTGIS ANXA2P2 ABCC4 SLC35B4</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">SKOV3</td><td align="center" valign="top" rowspan="1" colspan="1">167</td><td align="left" valign="top" rowspan="1" colspan="1">ACTB TSPAN1 RAB12 OSBPL11 L1CAM OSBPL10 LRRC20 RRAD ANKRD34B RNF38 HES2 SMC5 FAM3C PRKAA2 KCNH3 LMAN1 ST3GAL2 AFF1 TAF4B IFNGR1 FHDC1 CGNL1 CA13 SYPL1 MKNK2 SLC39A10 AMMECR1 ZNF114 GAS2L3 CERK BAG4 SASH1 C6orf228 TBC1D13 C7orf29,LRRC61 TUBB2B GTF2E1 ABCC3 PLCH1 CLDND1 MBP CYB5R4 SLC39A14 AKR1B10 CELSR2 PDZK1 FOXN3 PIK3R1 GRIN2B CIAPIN1 CORO1C RNFT1 UPP1 SHROOM2 FAM45A,FAM45B ANKRD33B ZNF702P ID4 PPM1B PER1 SLC44A1 CDH16 PCDH20 ADAM10 RNF130 CBS KIF12<xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref>KLHL15 ZNF28 ATP8B2 EGFR MIR4723,TMEM199 DICER1 DPP4 ITGB3 DENND1B SGK2 BASP1P1 USP18 RAB3D DCUN1D4 SNTB1 PGGT1B CNKSR3 CHST15 MCAM TYW1 GCH1 TRIM2 C12orf23 FNDC5 IGFN1 USP2 TERF1 SORT1 CRYAB GMCL1 WNT7A<xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref> MXRA5 AGL RNF144B ASRGL1 MPHOSPH6 QPRT AATF LIN7C NXT2 C2orf72 RRM2 BCAT1 SLC7A11 ADAMTS9 TMSB4X TPK1 KPNA6 ATP8A1 CHST2 THBS1 CYP4F11 RNF145 ADAMTS5 FLJ26245 SYTL2 UBE2H DCAF12L1 RAB11FIP2 ABI2 PTPRB FIGN PAFAH1B2 TCF12 PMAIP1 WDR44 DCUN1D3 SLC30A6 EPHA4 NEBL DSC2 CNOT6 ZNF611 MYO10 MAP2 KCNS3 SLC26A2 HDHD2 SLAIN1 PLXNC1 MGST1 NUPL1 COL12A1 KCTD5 RCBTB2 CANT1 MTPN FN1 UBE2D1 ZCCHC24 TMTC2 TRIM24 FAM174B C10orf26 TMCO7 GUCY1B3 ARHGEF1 ANKRD52 RC3H2 ZNF618</td></tr><tr><td align="center" valign="top" rowspan="1" colspan="1">FT194</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="left" valign="top" rowspan="1" colspan="1">KLHL13 ZNF185 PPARGC1A WASF1 PLAU KLHL14 TLL2 CHRD<xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref> CLGN NGFR ARHGEF37 FLG GAS7 TGFBR3 RGS20 ILDR2 SPON1 MMD CD24 AP1M2 TNFSF4 THY1 ADAMTS14 ZBED2<xref ref-type="table-fn" rid="tfn_001"><sup>a</sup></xref> PLCB4 ADAMTS1 LOC643201 NOV MPP7 SHISA2 ST3GAL1 SOX17 GDF6 ANK3 RASGEF1B CNTN4 C13orf15 SULF2 ADORA1 MEGF9 KLRG2 ITGB8 DANCR,SNORA26 SLC6A6 BAALC CTHRC1 G0S2 TMEM117 AIF1L GJB2 PRKAG2 FAT2 MST1 DCDC2 OXTR SDC2 INHBB KIAA1456 BTBD11 CA2 NID2 SLC47A1 CDH5 PDE1A COL13A1 IGFBP5 TMEM170B CTGF EPHB1 GPRC5C DKK1 CDKN1C</td></tr></tbody></table><table-wrap-foot><fn id="tfn_001"><label>a</label><p>Genes that were validated using qRT-PCR.</p></fn></table-wrap-foot></table-wrap><table-wrap orientation="portrait" id="d35e2180" position="anchor"><label>Table 3B</label><caption><title>List of shared and exclusive genes upregulated upon PAX8 silencing in SKOV-3 and FT194 cells</title></caption><table frame="box" rules="all"><thead><tr><th align="center" valign="middle" rowspan="1" colspan="1">Name</th><th align="center" valign="middle" rowspan="1" colspan="1">Total</th><th align="center" valign="middle" rowspan="1" colspan="1">Elements</th></tr></thead><tbody><tr><td align="left" valign="top" rowspan="1" colspan="1">SKOV3-FT194</td><td align="center" valign="top" rowspan="1" colspan="1">15</td><td align="left" valign="top" rowspan="1" colspan="1">ANKRD1 F3 G3BP2 TGFB2 MAPK1IP1L TOMM20 MBTPS1 DNMT3B PTPN1 MSRB3 MET RBPJ TCEB3 WDR1 STX12</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">SKOV3</td><td align="center" valign="top" rowspan="1" colspan="1">72</td><td align="left" valign="top" rowspan="1" colspan="1">DIO2<xref ref-type="table-fn" rid="tfn_002"><sup>b</sup></xref> ZCCHC3 NTN4 NGRN TRAPPC2 CALU MOK DCBLD1 PTPMT1 FGF1 C1D AHRR,PDCD6 LOC100507412,RN45S PCSK7 CPA4 CIRBP SERPINE1 C6orf120 PODXL CCDC80 DOCK10 PYGO2 P4HA3 MCFD2 DSEL MYPN LPXN CCND3 CHFR MAP2K4 GRWD1 CCBE1 UBE2G1,ZZEF1 BOD1<xref ref-type="table-fn" rid="tfn_002"><sup>b</sup></xref> NCF2 ODZ2 ERRFI1 CCIN SERPINB5 ATG12 CGB8 FLRT2 AIM1 ROS1 C7orf58 ALS2CL FRMD6 KRT5 SSFA2 PIP4K2A SOCS7 NT5E ESYT2 SMAP1 ARTN SCRN1 DKK1 EFEMP1 RFK SGK1 CCDC68 CRK FOXD1 PGM2L1 PCDH10 SEMA7A ZFAND3 IFFO2 CCNC RCAN1 KHNYN POLR3F</td></tr><tr><td align="left" valign="top" rowspan="1" colspan="1">FT194</td><td align="center" valign="top" rowspan="1" colspan="1">32</td><td align="left" valign="top" rowspan="1" colspan="1">CMPK2 RAD54L2 DDX58 IFIT1 SP110 PTPN13 DCN PAPPA<xref ref-type="table-fn" rid="tfn_002"><sup>b</sup></xref> RHOB CCL20 GBP1 SERPINB2<xref ref-type="table-fn" rid="tfn_002"><sup>b</sup></xref> OAS3 PDZD2 IFIH1 NCOA7 OAS2 RSAD2 PTGS2 MX1 ZCCHC2 CYP1B1 DHX58 DDX60L HMGA2 FARP2 MX2 NRK FPR1 THBD ST6GALNAC5 THBS2</td></tr></tbody></table><table-wrap-foot><fn id="tfn_002"><label>b</label><p>Genes that were validated using qRT-PCR.</p></fn></table-wrap-foot></table-wrap></table-wrap-group><p>We reasoned that genes modulated upon PAX8 silencing in both cell lines could be looked at as putative PAX8 targets with greater confidence. Hence, we focused our attention on the intersections between SKOV-3 and FT194 cells and we observed that they include several interesting genes such as: <italic>PSAP, FGF18, CDH6, ROR1, RBPJ</italic> and <italic>DNMT3B</italic> whose role in cell proliferation, cell survival and tumorigenic process has already been reported. In particular, PSAP (prosaposin) is a pleiotropic growth factor able to prevent cell death or apoptosis and to promote cell survival [<xref rid="R68" ref-type="bibr">68</xref>]; FGF18 controls migration, invasion and tumorigenicity of ovarian cancer cells [<xref rid="R69" ref-type="bibr">69</xref>]; CDH6 is a new TGF-beta target modulated as a mesenchymal marker in EMT [<xref rid="R52" ref-type="bibr">52</xref>]; ROR1, a receptor tyrosine kinase orphan receptor 1, is involved in migration, invasion and EMT in ovarian cancer cells [<xref rid="R70" ref-type="bibr">70</xref>]; RBPJ (recombination signal-binding protein Jk) is a key transcription factor in the Notch signaling pathway and its inhibition reduces cell growth [<xref rid="R71" ref-type="bibr">71</xref>]; DNMT3B encodes a DNA methyltransferase involved in de novo DNA methylation whose role in cancer development is not clear but several reports suggest a role as tumor suppressor [<xref rid="R72" ref-type="bibr">72</xref>].</p><p>At the same time, we believe that genes modulated upon PAX8 silencing exclusively in FT194 or in SKOV-3 cells should be considered relevant because they could reflect the continuous process from the precancerous to the cancerous condition. In addition, the tumorigenic process might itself promote the expression of some genes making them available for PAX8 transcriptional regulation. For example, WNT7A known to function as tumor-promoting in ovarian cancer [<xref rid="R73" ref-type="bibr">73</xref>] is present at very low level in FT194 cells but becomes highly expressed in SKOV-3 cells (<xref ref-type="supplementary-material" rid="SD2">Supplementary Table S1</xref>) where is significantly downregulated upon PAX8 silencing (<xref ref-type="supplementary-material" rid="SD4">Supplementary Table S3</xref> and Table <xref ref-type="table" rid="T3">3A</xref>). Similarly, ASRGL1 (asparaginase like 1) is highly expressed in ovarian carcinoma and confers a selective growth advantage [<xref rid="R74" ref-type="bibr">74</xref>]; accordingly, our data show that ASRGL1 is preferentially expressed in SKOV-3 cells where it is downregulated following PAX8 silencing (Table <xref ref-type="table" rid="T3">3A</xref>).</p><p>We validated the data obtained by RNA-seq by means of qRT-PCR for 13 genes, including PAX8. For these genes, we confirmed the different expression between the two cell types (Figure <xref ref-type="fig" rid="F3">3A</xref>) and in OVCAR-3, PEA1 and PEO14 ovarian cancer cell lines (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S1</xref>). The same genes were also validated upon silencing of PAX8 in FT194 and SKOV-3 cells (Figure <xref ref-type="fig" rid="F3">3B</xref> and <xref ref-type="fig" rid="F3">3C</xref>). In particular, we confirmed that KIF12, DIO2 and WNT7A are expressed preferentially in SKOV-3 cells (Figure <xref ref-type="fig" rid="F3">3A</xref>) and in these cells are modulated upon silencing of PAX8 (Figure <xref ref-type="fig" rid="F3">3B</xref>). At difference, FGF18, CDH6, ANXA2 and ROR1 are expressed and modulated in both cell lines (Figure <xref ref-type="fig" rid="F3">3A</xref>, <xref ref-type="fig" rid="F3">3B</xref>, <xref ref-type="fig" rid="F3">3C</xref>). CHRD, PAPPA and SERPINB2 are expressed almost exclusively in FT194 cells (Figure <xref ref-type="fig" rid="F3">3A</xref>) and are modulated upon silencing of PAX8 (Figure <xref ref-type="fig" rid="F3">3C</xref>). ZBED2 and BOD1 are expressed in both cell lines but following PAX8 silencing ZBED2 is modulated at significant level only in FT194 cells, while BOD1 only in SKOV-3 cells. To strengthen our observations we validated the same genes also in PEA1 cells after PAX8 silencing (<xref ref-type="supplementary-material" rid="SD1">Supplementary Figure S2</xref>).</p><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><title>Validation of representative genes by qRT-PCR analysis</title><p>(<bold>A</bold>) Expression levels of 13 genes measured on total RNA prepared from SKOV-3 and FT194 cells. The values are means &#x000b1; SD of three independent experiments in duplicate, normalized by the expression of IP08 and expressed as fold change with respect to FT194 cells. (<bold>B</bold> and <bold>C</bold>) Expression levels of some representative genes measured on total RNA prepared from FT194 and SKOV-3 cells transiently transfected with PAX8 siRNA or scramble siRNA 24 h (white bars), 48 h (black bars) and 72 h (grey bars) after transfection. The values are means &#x000b1; SD of three independent experiments in duplicate, normalized by the expression of IP08 and expressed as fold change with respect to the cells transfected with the scramble siRNA, whose value was set at 1.0. <italic>p</italic>-value was calculated by <italic>t</italic>-test 0.001 &#x02264; <italic>p</italic> &#x02264; 0.1.</p></caption><graphic xlink:href="oncotarget-07-41929-g003"/></fig><p>Subsequently, we analyzed the 5&#x02032;-flanking regions of the genes commonly regulated in the two cell lines in order to recognize DNA binding motifs for PAX8 matrices using the PASTAA method (<ext-link ext-link-type="uri" xlink:href="http://trap.molgen.mpg.de/">http://trap.molgen.mpg.de</ext-link>) [<xref rid="R75" ref-type="bibr">75</xref>] which utilizes the prediction of binding affinities of a transcription factor to regulatory regions. The genes containing PAX8 DNA binding motifs were ranked according to the prediction of binding affinity of their 5&#x02032;-flanking region to the PAX8 binding sites (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S5</xref>). To unambiguously determine whether PAX8 directly binds to the above mentioned regulative genomic sequences, we performed a computational analysis for some representative genes chosen among those commonly regulated in the FT194 and SKOV3 cells, using the MatInspector Software (Genomatix). We searched for PAX8 binding sites in a region of about 2 Kb in their 5&#x02032;-flanking region and we found several PAX8 consensus sequences. To confirm the predictions of the MatInspector analysis, we carried out chromatin immunoprecipitation (ChIP) assays on FT194 cells using a polyclonal antibody against PAX8. The ChIP results indicate that <italic>in vivo</italic> PAX8 is able to bind the regulatory regions of all selected genes (Figure <xref ref-type="fig" rid="F4">4</xref>).</p><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><title>Direct binding of PAX8 on the regulatory regions of putative target genes</title><p>Chromatin immunoprecipitation assays were performed to determine the binding of PAX8 to the 5&#x02032;-flanking region of representative genes. Chromatin was subjected to quantitative real-time PCR analysis using appropriate primers (see Materials and Methods). Error bars indicate s.d. between two experiments performed in duplicate (<italic>p</italic> &#x0003c; 0,001).</p></caption><graphic xlink:href="oncotarget-07-41929-g004"/></fig><p>All together, our results show that the expression profiles affected by PAX8 silencing might reflect an ongoing transformation process reinforcing the involvement of this transcription factor in ovarian cancer.</p></sec><sec id="s2_4"><title>Pathways regulated by PAX8 in ovarian cancer</title><p>The pathways that PAX8 may regulate in ovarian cancer and in Fallopian tube secretory cells are still undefined. To categorize PAX8 associated pathways that are represented in our PAX8-silenced SKOV-3 and FT194 cells, we classified all the dysregulated genes (301 for SKOV-3 and 166 for FT194) using the Gene annotations co-occurrence discovery web-based tool (GeneCodis; <ext-link ext-link-type="uri" xlink:href="http://genecodis.dacya.ucm.es/">http://genecodis.dacya.ucm.es/</ext-link>). Several significant GO categories appeared enriched including signal transduction, cell adhesion, blood coagulation, positive regulation of cell migration, angiogenesis and cell differentiation (Figure <xref ref-type="fig" rid="F5">5A</xref> and <xref ref-type="fig" rid="F5">5B</xref>). At the same time, the most affected pathways upon silencing of PAX8 comprise Wnt signaling, cadherin signaling, integrin signaling and TGF-beta signaling (Figure <xref ref-type="fig" rid="F5">5C</xref> and <xref ref-type="fig" rid="F5">5D</xref>).</p><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><title>Biological processes and pathways altered in siPAX8 cells</title><p>Gene ontology (GO) and Panther pathway anlysis have been performed using GeneCodis (<ext-link ext-link-type="uri" xlink:href="http://genecodis.dacya.ucm.es/">http://genecodis.dacya.ucm.es/</ext-link>). (<bold>A</bold>) GO categories enriched for genes modulated upon PAX8 silencing in SKOV-3 cells. (<bold>B</bold>) GO categories enriched for genes modulated upon PAX8 silencing in FT194 cells. (<bold>C</bold>) Panther pathways enriched for genes modulated upon PAX8 silencing in SKOV-3 cells. (<bold>D</bold>) Panther pathways enriched for genes modulated upon PAX8 silencing in FT194 cells.</p></caption><graphic xlink:href="oncotarget-07-41929-g005"/></fig><p>To further investigate the functional associations of downregulated and upregulated genes following PAX8 knockdown we performed an MsigDB analysis. Interestingly, we observed that for the significantly upregulated genes (87 for SKOV-3 and 47 for FT194) the most affected pathways in both cells lines are interferon response, TNFa signaling, inflammatory response, apoptosis, UV response and epithelial mesenchymal transition (Figure <xref ref-type="fig" rid="F6">6</xref>). In the same way, for the downregulated genes (214 for SKOV-3 and 119 for FT194) the most affected pathways in both cells lines are epithelial mesenchymal transition, UV response, Kras signaling, estrogen response and p53 pathway (Figure <xref ref-type="fig" rid="F6">6</xref>). In agreement with our previous studies, the pathways perturbed upon PAX8 silencing such as IFN-g and TGF-a signaling, EMT, apoptosis, hypoxia as well as UV response strengthen the new role of PAX8 in the regulation of cell survival, proliferation and in the maintenance of oncogenic properties [<xref rid="R11" ref-type="bibr">11</xref>, <xref rid="R17" ref-type="bibr">17</xref>].</p><fig id="F6" orientation="portrait" position="float"><label>Figure 6</label><caption><title>Pathway analysis of differentially expressed genes after PAX8 silencing</title><p>MsigDB software was used to identify the pathways most affected by the gene dysregulation. (<bold>A</bold>) MsigDB for SKOV-3 downregulated (black bars) and upregulated genes (gray bars). (<bold>B</bold>) MsigDB for FT194 downregulated (black bars) and upregulated genes (gray bars).</p></caption><graphic xlink:href="oncotarget-07-41929-g006"/></fig><p>In conclusion, we think that the majority of the genes affected by PAX8 silencing are associated with important biological cellular processes and we believe that our analysis provides a solid basis for the identification of relevant molecules involved in ovarian cancer.</p></sec></sec><sec id="s3"><title>DISCUSSION</title><p>Recent studies suggest that a substantial proportion of cases of ovarian high-grade serous carcinoma may arise from precursor lesions located in the Fallopian tubal epithelium (FTE). In our study, by means of RNA-seq analysis we investigated the expression of genes modified during the transformation process from Fallopian tube secretory epithelial cells to HGSC cells. Moreover, genes and pathways downstream the transcription factor PAX8 have been analyzed in both cell types. Our goal was to identify new targets for diagnostic and/or therapeutic approaches for HGSC that is the third most common cause of death among gynecologic malignancies worldwide. Actually, improved screening strategies for HGSC diagnosis in early stages, as well as effective treatments are greatly needed.</p><p>We highlighted that &#x02248; 60% of the genes differentially expressed between the two cell types is modulated at a significant level (FDR-adjusted <italic>p</italic>-value &#x02264; 0.05). Applying a 2 fold-change cutoff and performing a Molecular Signatures Database analysis, we determined in SKOV-3 cells a significant enrichment of estrogen response, EMT, angiogenesis and Wnt/&#x003b2; catenin pathways. At the same time, in FT194 cells we observed an enrichment of pathways like TNF-&#x003b1;, IFN-&#x003b1;, IFN-&#x003b3; and inflammatory responses. Furthermore, we consider intriguing those genes that turned out to be preferentially, or in some cases exclusively, expressed in FT194 or SKOV-3 cells. There is no doubt that the future challenge will be to examine the potential role of genes differentially expressed between the two cell types as specific and sensitive biomarkers. In fact, several ovarian cancer screening studies have established that acombinatorial biomarker strategy is more reliable, sensitive and specific than using a single protein biomarker [<xref rid="R76" ref-type="bibr">76</xref>]. A recent study identified a 5-marker panel for early detection of ovarian cancer that includes five serum biomarkers, namely macrophage-stimulating protein alpha, tissue inhibitor of metalloproteinases-4, platelet-derived growth factor receptor alpha (PDGF-R alpha), osteoprotegerin, and CA-125 [<xref rid="R77" ref-type="bibr">77</xref>]. Preliminary insights that we obtained using ProteINSIDE, a novel web service [<xref rid="R78" ref-type="bibr">78</xref>], suggest that among the genes highly expressed in SKOV-3 cells there are some that encode for secreted proteins like CGB5 [<xref rid="R79" ref-type="bibr">79</xref>], CGB8 [<xref rid="R79" ref-type="bibr">79</xref>], FOLR1 [<xref rid="R28" ref-type="bibr">28</xref>], SPP1 [<xref rid="R80" ref-type="bibr">80</xref>], IGFBP3 [<xref rid="R81" ref-type="bibr">81</xref>], NFASC [<xref rid="R82" ref-type="bibr">82</xref>] emphasizing that our study may indeed provide a solid basis for the identification of new biomarkers. Of interest, among the top genes highly expressed in SKOV-3 cells there is PRAME that in a wide variety of human malignancies correlates with poor clinical outcome [<xref rid="R83" ref-type="bibr">83</xref>]. It has been reported that PRAME proteins are associated to self-renewal cell maintenance [<xref rid="R84" ref-type="bibr">84</xref>] and are currently considered as potential target to hamper cancer cell proliferation [<xref rid="R85" ref-type="bibr">85</xref>].</p><p>In 2003, a gene expression study carried out in ovarian carcinoma [<xref rid="R86" ref-type="bibr">86</xref>] reported the transcription factor PAX8, normally absent in ovarian surface epithelial cells, among the most highly expressed genes. The recent carcinogenesis model proposes the secretory cells of the Fallopian tubal mucosa as the cell of origin for the majority of EOC. In agreement with this hypothesis, PAX8 would not be overexpressed in epithelial ovarian carcinoma but rather its expression would be conserved from the cell of origin [<xref rid="R38" ref-type="bibr">38</xref>]. To date, the function of PAX8 in Fallopian tube epithelial secretory cells has not been clarified. It has been demonstrated a continually regulated cycle of growth, differentiation, death and renewal in the epithelium of the mammalian oviduct [<xref rid="R87" ref-type="bibr">87</xref>] and in this context PAX8 could exert its role. However, more studies are needed to shed light on the function of this transcription factor in this cell type.</p><p>We have recently reported that PAX8 is involved in the tumorigenic phenotype of ovarian cancer cells [<xref rid="R17" ref-type="bibr">17</xref>]. In the present study, we intend to clarify PAX8 contribution to ovarian cancer through the identification of its downstream gene regulatory network. MsigDB analysis revealed that in both FT194 and SKOV-3 cells the most affected pathways are interferon response, TNFa signaling, inflammatory response, apoptosis, UV response and epithelial mesenchymal transition (considering the upregulated genes) and epithelial mesenchymal transition, UV response, estrogen response and p53 pathway (considering the downregulated genes). Interestingly, our RNA-seq analysis identifies, among PAX8 potential targets, genes that have been reported in the literature having a role in ovarian cancer. One of such genes is FGF18 whose expression is significantly reduced after PAX8 knockdown. It has been demonstrated that FGF18 regulates both tumor cells and tumor microenvironment to facilitate the progression of serous ovarian cancer, enhancing angiogenesis and tumor-associated macrophage infiltration [<xref rid="R69" ref-type="bibr">69</xref>, <xref rid="R88" ref-type="bibr">88</xref>]. In addition, FGF18 was identified as the gene possessing the strongest prognostic value in segment 5q31-5q35.3 that was found amplified on microdissected HGSC samples [<xref rid="R89" ref-type="bibr">89</xref>]. Furthermore, a recent study provides a platform for the identification of blood-based biomarkers (&#x0201c;Secretome&#x0201d;) for high-grade, advanced-stage serous ovarian tumors and identifies two new markers, FGF18 and GPR172 [<xref rid="R90" ref-type="bibr">90</xref>]. Here, we hypothesize that one way in which PAX8 confers a proliferative advantage to ovarian cancer cells is through the regulation of procancer factors, like FGF18, in a pathological microenvironment.</p><p>Abnormal activation of the WNT/b-catenin signaling pathway has been associated with ovarian carcinomas. It has been reported that WNT7A is abundantly expressed in ovarian carcinoma and is able to control cell division, adhesion and motility [<xref rid="R73" ref-type="bibr">73</xref>]. In addition, WNT7A knockdown cancer cells show a significantly decreased growth rate and invasion ability in a xenografts model [<xref rid="R73" ref-type="bibr">73</xref>]. Intriguingly, the phenotype of WNT7A knockdown xenografts resembles that described for the xenograft model of the siPAX8-SKOV-3 cells [<xref rid="R17" ref-type="bibr">17</xref>] and this study shows that WNT7A is abundantly expressed only in SKOV-3 cells where is a downstream target of PAX8.</p><p>In addition, the expression of some genes regulated by PAX8 in Fallopian tubes secretory cells may be lost during the neoplastic transformation. For example, our data show that chordin (CHRD), a BMP extracellular regulator that behaves as suppressor of tumorigenesis in ovarian carcinoma cells, is abundantly expressed and regulated by PAX8 in FT194 cells, while is almost absent in SKOV-3 cells.</p><p>It is worth noting that it has recently been demonstrated that Fallopian tube secretory cell expansion and the ratio between secretory/ciliated cells (S/C ratio) are linked to pelvic serous neoplasia [<xref rid="R91" ref-type="bibr">91</xref>] and in this scenario the cancer cells of the serous tubal intraepithelial carcinoma (STIC) bearing a &#x0201c;p53 signature&#x0201d; invade onto the ovary and implant on peritoneal surfaces [<xref rid="R92" ref-type="bibr">92</xref>&#x02013;<xref rid="R94" ref-type="bibr">94</xref>]. During this process, the secretory cells retain the expression of PAX8 that possibly continues to exert its transcriptional activity on its physiological targets and in addition may also function on new targets that become available after the tumorigenic hits (BRCA mutations, p53 signature etc).</p><p>Our final suggestion is that the relevance of PAX8 in ovarian carcinoma lies in the downstream network(s) regulated by this transcription factor that contribute to ovarian carcinoma pathogenesis. In this respect, we believe that our study has led to the identification of genes and pathways regulated by PAX8 that could be valuable for future studies to uncover the molecular mechanisms leading to EOC.</p></sec><sec sec-type="methods" id="s4"><title>MATERIALS AND METHODS</title><sec id="s4_1"><title>Cell culture and RNA interference</title><p>The human ovarian carcinoma cell line SKOV-3 was obtained from the CEINGE Cell Culture Facility (Naples, Italy) and was grown in RPMI-1640 medium (Euroclone) containing 10% fetal bovine serum (Euroclone). The immortalized Fallopian tube secretory epithelial cell line FT194 was kindly provided by Dr. R. Drapkin (Boston, USA) and was maintained in DME-F12 medium (Euroclone) containing 2% Ultroser G serum (PALL). The OVCAR-3 cell line was obtained from ATCC and was maintained in RPMI-1640 medium (Euroclone) containing 20% fetal bovine serum (Euroclone) and 0.01 mg/ml bovine insulin. PEA1 and PEO14 cells were purchased from Sigma-Aldrich and mantained in RPMI-1640 medium (Euroclone) containing 10% fetal bovine serum (Euroclone), 2 mM glutamine and 2 mM sodium pyruvate (Gibco, Life Technologies).</p><p>For RNA interference, SKOV-3, FT194 cells and PEA1 were plated at 2 &#x000d7; 10<sup>5</sup> cells/60-mm tissue culture dish 24 h prior to transfection and were transfected in replicates with 5 nM PAX8 siRNA (Ambion, Life Techonologies, siRNA ID s15403) or siRNANon-Targeting (Ambion, Life Technologies, siRNA ID 4390843) as scramble, using the Lipofectamine RNAiMAX transfection reagent (Invitrogen) following the manufacturer's protocol. Cells were harvested 24 h after transfection and the total RNA was prepared. Human Fallopian tubes RNA was from Origene (CR559726).</p></sec><sec id="s4_2"><title>RNA extraction, qRT&#x02013;PCR, RNA-seq and data mining</title><p>For both qRT-PCR and RNA-seq experiments, total RNA was extracted using the RNeasy Mini kit (Qiagen). For qRT-PCR, the cDNA was synthesized using the iScript cDNA Synthesis kit (BIORAD, Hercules, CA). Real time RT&#x02013;PCR analysis was performed using the IQ<sup>&#x02122;</sup> SYBR Green PCR Master Mix (BIORAD) in a CFX96 Real-Time PCR Detection System (BIORAD) with gene-specific oligonucleotides (<xref ref-type="supplementary-material" rid="SD1">Supplementary Table S6</xref>).</p><p>For RNA-seq, 2 &#x003bc;g of total RNA extracted 24 h after transfection were sent to the Genomics4Life Company (University of Salerno, Italy). Independent silencing experiments were performed from which biological replicates of each condition (siPAX8 or control) were processed for the RNA-seq analysis.</p><p>The extracted RNA samples were sequenced using the Illumina HiSeq 1500 platform, TruSeq Stranded Total RNA, 100 bp paired-end reads at the Genomics4Life Company (University of Salerno, Italy).</p><p>Analysis was performed using the EPIGEN project sequence facility, RAP (RNA-Seq Analysis Pipeline) [<xref rid="R95" ref-type="bibr">95</xref>], available on the following website <ext-link ext-link-type="uri" xlink:href="https://bioinformatics.cineca.it/">https://bioinformatics.cineca.it/</ext-link>. Sequence quality was assessed using FastQC (<ext-link ext-link-type="uri" xlink:href="http://www.bioinformatics.babraham.ac.uk/projects/fastqc/">http://www.bioinformatics.babraham.ac.uk/projects/fastqc/</ext-link>) and NGS QC Toolkit [<xref rid="R96" ref-type="bibr">96</xref>], using default parameters (PHRED quality score: 20 and for percentage of read length of given quality: 70). Hence, paired-end reads were mapped to the reference human genome build (hg19/GRCh37) using Tophat 2.0.12 [<xref rid="R97" ref-type="bibr">97</xref>] with default parameters. The resulting alignment files are provided to Cufflinks [<xref rid="R98" ref-type="bibr">98</xref>] to generate a transcriptome assembly and to estimate the expression level expressed as units of FPKM (Fragment mapped per kilobase of exons per million mapped reads). Differential expression analyses were performed with Cuffdiff2 [<xref rid="R99" ref-type="bibr">99</xref>] using default parameters. An alpha level of 0.05 was used for all statistical tests. Gene expression data have been submitted to the Gene Expression Omnibus (GEO), Accession number GSE79572.</p></sec><sec id="s4_3"><title>Chromatin immunoprecipitation assay</title><p>ChIP was performed as previously described [<xref rid="R100" ref-type="bibr">100</xref>]. Precleared chromatin from FT194 cells was incubated with 3 &#x003bc;g of affinity-purified rabbit polyclonal anti-PAX8 antibody (Thermo Scientific, PA1-112) or polyclonal anti-TAZ antibody as unrelated (Santa Cruz Biotechnology, sc-17130) and rotated at 4&#x000b0;C for 16 h. Thereafter, the immunoprecipitated DNAs were amplified by quantitative real-time PCR with the following primers:</p><p>FGF18 for. 5&#x02032;-gtgggtagccagtcaagagg-3&#x02032;; rev. 5&#x02032;-ctccccaagaacgcagttag-3&#x02032;;</p><p>ANXA2 for. 5&#x02032;-Gctaaacggctgcaagaaac-3&#x02032;; rev. 5&#x02032;-Cgtagcaggcagtcctgag-3&#x02032;;</p><p>CDH6 for. 5&#x02032;-Atccaacagtggctgactcc-3&#x02032;; rev. 5&#x02032;-tctggaaagttgccgaagtt-3&#x02032;;</p><p>ROR1 for. 5&#x02032;-CAGATCACAGCTGCCTTCAC-3&#x02032;; rev. 5&#x02032;-ATTTCACATTCATCGCGACA-3&#x02032;.</p></sec><sec id="s4_4"><title>Pathway analysis</title><p>Gene ontology (GO) and Panther pathway analysis have been performed using the GeneCodis tool (<ext-link ext-link-type="uri" xlink:href="http://genecodis.cnb.csic.es/">http://genecodis.cnb.csic.es</ext-link>) previously described in references [<xref rid="R101" ref-type="bibr">101</xref>&#x02013;<xref rid="R103" ref-type="bibr">103</xref>].</p><p>Genes showing a two-fold change in expression were analyzed at Molecular Signatures Database (<ext-link ext-link-type="uri" xlink:href="http://software.broadinstitute.org/gsea/msigdb">http://software.broadinstitute.org/gsea/msigdb</ext-link>) using the &#x0201c;Hallmark&#x0201d; gene set.</p></sec></sec><sec sec-type="supplementary-material" id="s5"><title>SUPPLEMENTARY FIGURES AND TABLES</title><supplementary-material content-type="local-data" id="SD1"><media mimetype="application" mime-subtype="pdf" xlink:href="oncotarget-07-41929-s001.pdf" orientation="portrait" xlink:type="simple" id="d35e2654" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-07-41929-s002.xlsx" orientation="portrait" xlink:type="simple" id="d35e2656" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-07-41929-s003.xlsx" orientation="portrait" xlink:type="simple" id="d35e2658" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-07-41929-s004.xlsx" orientation="portrait" xlink:type="simple" id="d35e2660" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><media mimetype="application" mime-subtype="xlsx" xlink:href="oncotarget-07-41929-s005.xlsx" orientation="portrait" xlink:type="simple" id="d35e2662" position="anchor"/></supplementary-material></sec></body><back><ack><title>ACKNOWLEDGMENTS AND FUNDING</title><p>We greatly thank L. Nitsch and M. De Felice for helpful discussions and suggestions.</p></ack><fn-group><fn fn-type="COI-statement"><p><bold>CONFLICT OF INTEREST</bold></p><p>The authors declare that they have no known conflicts of interest in this work.</p></fn><fn fn-type="supported-by"><p><bold>GRANT SUPPORT</bold></p><p>This work was supported by a grant from the Italian Ministry of Economy and Finance to the CNR for the Project FaReBio di Qualit&#x000e0;, by the grant Medical Research in Italy (MERIT) RBNE08YFN3_001 and by the Epigenomic Flagship Project-Epigen of the CNR.</p><p>O.A. is a recipient of a doctoral fellowship from the Ph.D. of Computational Biology and Bioinformatics, University of Naples Federico II, Naples, Italy.</p><p>A.A.S. is a recipient of a doctoral fellowship from the Ph.D. of Molecular Medicine and Medical Biotechnology, University of Naples Federico II, Naples, Italy.</p></fn></fn-group><ref-list><title>REFERENCES</title><ref id="R1"><label>1</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saad</surname><given-names>AF</given-names></name><name><surname>Hu</surname><given-names>W</given-names></name><name><surname>Sood</surname><given-names>AK</given-names></name></person-group><article-title>Microenvironment and pathogenesis of epithelial ovarian cancer</article-title><source>Horm Cancer</source><year>2010</year><volume>1</volume><fpage>277</fpage><lpage>290</lpage><pub-id pub-id-type="pmid">21761359</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Shaw</surname><given-names>PA</given-names></name><name><surname>McLaughlin</surname><given-names>JR</given-names></name><name><surname>Zweemer</surname><given-names>RP</given-names></name><name><surname>Narod</surname><given-names>SA</given-names></name><name><surname>Risch</surname><given-names>H</given-names></name><name><surname>Verheijen</surname><given-names>RH</given-names></name><name><surname>Ryan</surname><given-names>A</given-names></name><name><surname>Menko</surname><given-names>FH</given-names></name><name><surname>Kenemans</surname><given-names>P</given-names></name><name><surname>Jacobs</surname><given-names>IJ</given-names></name></person-group><article-title>Histopathologic features of genetically determined ovarian cancer</article-title><source>Int J Gynecol Pathol</source><year>2002</year><volume>21</volume><fpage>407</fpage><lpage>411</lpage><pub-id pub-id-type="pmid">12352190</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nik</surname><given-names>NN</given-names></name><name><surname>Vang</surname><given-names>R</given-names></name><name><surname>Shih Ie</surname><given-names>M</given-names></name><name><surname>Kurman</surname><given-names>RJ</given-names></name></person-group><article-title>Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma</article-title><source>Annu Rev Pathol</source><year>2014</year><volume>9</volume><fpage>27</fpage><lpage>45</lpage><pub-id pub-id-type="pmid">23937438</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Perets</surname><given-names>R</given-names></name><name><surname>Wyant</surname><given-names>GA</given-names></name><name><surname>Muto</surname><given-names>KW</given-names></name><name><surname>Bijron</surname><given-names>JG</given-names></name><name><surname>Poole</surname><given-names>BB</given-names></name><name><surname>Chin</surname><given-names>KT</given-names></name><name><surname>Chen</surname><given-names>JY</given-names></name><name><surname>Ohman</surname><given-names>AW</given-names></name><name><surname>Stepule</surname><given-names>CD</given-names></name><name><surname>Kwak</surname><given-names>S</given-names></name><name><surname>Karst</surname><given-names>AM</given-names></name><name><surname>Hirsch</surname><given-names>MS</given-names></name><name><surname>Setlur</surname><given-names>SR</given-names></name><etal/></person-group><article-title>Transformation of the fallopian tube secretory epithelium leads to high-grade serous ovarian cancer in Brca;Tp53;Pten models</article-title><source>Cancer Cell</source><year>2013</year><volume>24</volume><fpage>751</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">24332043</pub-id></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cheung</surname><given-names>HW</given-names></name><name><surname>Cowley</surname><given-names>GS</given-names></name><name><surname>Weir</surname><given-names>BA</given-names></name><name><surname>Boehm</surname><given-names>JS</given-names></name><name><surname>Rusin</surname><given-names>S</given-names></name><name><surname>Scott</surname><given-names>JA</given-names></name><name><surname>East</surname><given-names>A</given-names></name><name><surname>Ali</surname><given-names>LD</given-names></name><name><surname>Lizotte</surname><given-names>PH</given-names></name><name><surname>Wong</surname><given-names>TC</given-names></name><name><surname>Jiang</surname><given-names>G</given-names></name><name><surname>Hsiao</surname><given-names>J</given-names></name><name><surname>Mermel</surname><given-names>CH</given-names></name><etal/></person-group><article-title>Systematic investigation of genetic vulnerabilities across cancer cell lines reveals lineage-specific dependencies in ovarian cancer</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>12372</fpage><lpage>12377</lpage><pub-id pub-id-type="pmid">21746896</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dahl</surname><given-names>E</given-names></name><name><surname>Koseki</surname><given-names>H</given-names></name><name><surname>Balling</surname><given-names>R</given-names></name></person-group><article-title>Pax genes and organogenesis</article-title><source>Bioessays</source><year>1997</year><volume>19</volume><fpage>755</fpage><lpage>765</lpage><pub-id pub-id-type="pmid">9297966</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bouchard</surname><given-names>M</given-names></name><name><surname>Souabni</surname><given-names>A</given-names></name><name><surname>Mandler</surname><given-names>M</given-names></name><name><surname>Neubuser</surname><given-names>A</given-names></name><name><surname>Busslinger</surname><given-names>M</given-names></name></person-group><article-title>Nephric lineage specification by Pax2 and Pax8</article-title><source>Genes Dev</source><year>2002</year><volume>16</volume><fpage>2958</fpage><lpage>2970</lpage><pub-id pub-id-type="pmid">12435636</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Plachov</surname><given-names>D</given-names></name><name><surname>Chowdhury</surname><given-names>K</given-names></name><name><surname>Walther</surname><given-names>C</given-names></name><name><surname>Simon</surname><given-names>D</given-names></name><name><surname>Guenet</surname><given-names>JL</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name></person-group><article-title>Pax8, a murine paired box gene expressed in the developing excretory system and thyroid gland</article-title><source>Development</source><year>1990</year><volume>110</volume><fpage>643</fpage><lpage>651</lpage><pub-id pub-id-type="pmid">1723950</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ozcan</surname><given-names>A</given-names></name><name><surname>Liles</surname><given-names>N</given-names></name><name><surname>Coffey</surname><given-names>D</given-names></name><name><surname>Shen</surname><given-names>SS</given-names></name><name><surname>Truong</surname><given-names>LD</given-names></name></person-group><article-title>PAX2 and PAX8 expression in primary and metastatic mullerian epithelial tumors: a comprehensive comparison</article-title><source>Am J Surg Pathol</source><year>2011</year><volume>35</volume><fpage>1837</fpage><lpage>1847</lpage><pub-id pub-id-type="pmid">21989345</pub-id></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Poleev</surname><given-names>A</given-names></name><name><surname>Fickenscher</surname><given-names>H</given-names></name><name><surname>Mundlos</surname><given-names>S</given-names></name><name><surname>Winterpacht</surname><given-names>A</given-names></name><name><surname>Zabel</surname><given-names>B</given-names></name><name><surname>Fidler</surname><given-names>A</given-names></name><name><surname>Gruss</surname><given-names>P</given-names></name><name><surname>Plachov</surname><given-names>D</given-names></name></person-group><article-title>PAX8, a human paired box gene: isolation and expression in developing thyroid, kidney and Wilms' tumors</article-title><source>Development</source><year>1992</year><volume>116</volume><fpage>611</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">1337742</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Palma</surname><given-names>T</given-names></name><name><surname>Filippone</surname><given-names>MG</given-names></name><name><surname>Pierantoni</surname><given-names>GM</given-names></name><name><surname>Fusco</surname><given-names>A</given-names></name><name><surname>Soddu</surname><given-names>S</given-names></name><name><surname>Zannini</surname><given-names>M</given-names></name></person-group><article-title>Pax8 has a critical role in epithelial cell survival and proliferation</article-title><source>Cell Death Dis</source><year>2013</year><volume>4</volume><fpage>e729</fpage><pub-id pub-id-type="pmid">23868062</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Raman</surname><given-names>P</given-names></name><name><surname>Koenig</surname><given-names>RJ</given-names></name></person-group><article-title>Pax-8-PPAR-gamma fusion protein in thyroid carcinoma</article-title><source>Nat Rev Endocrinol</source><year>2014</year><volume>10</volume><fpage>616</fpage><lpage>623</lpage><pub-id pub-id-type="pmid">25069464</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sangoi</surname><given-names>AR</given-names></name><name><surname>Ohgami</surname><given-names>RS</given-names></name><name><surname>Pai</surname><given-names>RK</given-names></name><name><surname>Beck</surname><given-names>AH</given-names></name><name><surname>McKenney</surname><given-names>JK</given-names></name><name><surname>Pai</surname><given-names>RK</given-names></name></person-group><article-title>PAX8 expression reliably distinguishes pancreatic well-differentiated neuroendocrine tumors from ileal and pulmonary well-differentiated neuroendocrine tumors and pancreatic acinar cell carcinoma</article-title><source>Mod Pathol</source><year>2011</year><volume>24</volume><fpage>412</fpage><lpage>424</lpage><pub-id pub-id-type="pmid">20890270</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>YJ</given-names></name><name><surname>Campbell</surname><given-names>HG</given-names></name><name><surname>Wiles</surname><given-names>AK</given-names></name><name><surname>Eccles</surname><given-names>MR</given-names></name><name><surname>Reddel</surname><given-names>RR</given-names></name><name><surname>Braithwaite</surname><given-names>AW</given-names></name><name><surname>Royds</surname><given-names>JA</given-names></name></person-group><article-title>PAX8 regulates telomerase reverse transcriptase and telomerase RNA component in glioma</article-title><source>Cancer Res</source><year>2008</year><volume>68</volume><fpage>5724</fpage><lpage>5732</lpage><pub-id pub-id-type="pmid">18632625</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>M</given-names></name><name><surname>Ma</surname><given-names>H</given-names></name><name><surname>Pan</surname><given-names>Y</given-names></name><name><surname>Xiao</surname><given-names>W</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Yu</surname><given-names>J</given-names></name><name><surname>He</surname><given-names>J</given-names></name></person-group><article-title>PAX2 and PAX8 reliably distinguishes ovarian serous tumors from mucinous tumors</article-title><source>Appl Immunohistochem Mol Morphol</source><year>2015</year><volume>23</volume><fpage>280</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">24992169</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Heidarpour</surname><given-names>M</given-names></name><name><surname>Tavanafar</surname><given-names>Z</given-names></name></person-group><article-title>Diagnostic utility of PAX8 in differentiation of mullerian from non-mullerian tumors</article-title><source>Adv Biomed Res</source><year>2014</year><volume>3</volume><fpage>96</fpage><pub-id pub-id-type="pmid">24800185</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Palma</surname><given-names>T</given-names></name><name><surname>Lucci</surname><given-names>V</given-names></name><name><surname>de Cristofaro</surname><given-names>T</given-names></name><name><surname>Filippone</surname><given-names>MG</given-names></name><name><surname>Zannini</surname><given-names>M</given-names></name></person-group><article-title>A role for PAX8 in the tumorigenic phenotype of ovarian cancer cells</article-title><source>BMC Cancer</source><year>2014</year><volume>14</volume><fpage>292</fpage><pub-id pub-id-type="pmid">24766781</pub-id></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karst</surname><given-names>AM</given-names></name><name><surname>Levanon</surname><given-names>K</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name></person-group><article-title>Modeling high-grade serous ovarian carcinogenesis from the fallopian tube</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>7547</fpage><lpage>7552</lpage><pub-id pub-id-type="pmid">21502498</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Modugno</surname><given-names>F</given-names></name><name><surname>Laskey</surname><given-names>R</given-names></name><name><surname>Smith</surname><given-names>AL</given-names></name><name><surname>Andersen</surname><given-names>CL</given-names></name><name><surname>Haluska</surname><given-names>P</given-names></name><name><surname>Oesterreich</surname><given-names>S</given-names></name></person-group><article-title>Hormone response in ovarian cancer: time to reconsider as a clinical target?</article-title><source>Endocr Relat Cancer</source><year>2012</year><volume>19</volume><fpage>R255</fpage><lpage>279</lpage><pub-id pub-id-type="pmid">23045324</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maleki</surname><given-names>J</given-names></name><name><surname>Nourbakhsh</surname><given-names>M</given-names></name><name><surname>Shabani</surname><given-names>M</given-names></name><name><surname>Korani</surname><given-names>M</given-names></name><name><surname>Nourazarian</surname><given-names>SM</given-names></name><name><surname>Ostadali Dahaghi</surname><given-names>MR</given-names></name><name><surname>Moghadasi</surname><given-names>MH</given-names></name></person-group><article-title>17beta-Estradiol Stimulates Generation of Reactive Species Oxygen and Nitric Oxide in Ovarian Adenocarcinoma Cells (OVCAR 3)</article-title><source>Iran J Cancer Prev</source><year>2015</year><volume>8</volume><fpage>e2332</fpage><pub-id pub-id-type="pmid">26413252</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Herr</surname><given-names>P</given-names></name><name><surname>Hausmann</surname><given-names>G</given-names></name><name><surname>Basler</surname><given-names>K</given-names></name></person-group><article-title>WNT secretion and signalling in human disease</article-title><source>Trends Mol Med</source><year>2012</year><volume>18</volume><fpage>483</fpage><lpage>493</lpage><pub-id pub-id-type="pmid">22796206</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gatcliffe</surname><given-names>TA</given-names></name><name><surname>Monk</surname><given-names>BJ</given-names></name><name><surname>Planutis</surname><given-names>K</given-names></name><name><surname>Holcombe</surname><given-names>RF</given-names></name></person-group><article-title>Wnt signaling in ovarian tumorigenesis</article-title><source>Int J Gynecol Cancer</source><year>2008</year><volume>18</volume><fpage>954</fpage><lpage>962</lpage><pub-id pub-id-type="pmid">17986238</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Arend</surname><given-names>RC</given-names></name><name><surname>Londono-Joshi</surname><given-names>AI</given-names></name><name><surname>Straughn</surname><given-names>JM</given-names><suffix>Jr</suffix></name><name><surname>Buchsbaum</surname><given-names>DJ</given-names></name></person-group><article-title>The Wnt/beta-catenin pathway in ovarian cancer: a review</article-title><source>Gynecol Oncol</source><year>2013</year><volume>131</volume><fpage>772</fpage><lpage>779</lpage><pub-id pub-id-type="pmid">24125749</pub-id></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoo</surname><given-names>HJ</given-names></name><name><surname>Byun</surname><given-names>HJ</given-names></name><name><surname>Kim</surname><given-names>BR</given-names></name><name><surname>Lee</surname><given-names>KH</given-names></name><name><surname>Park</surname><given-names>SY</given-names></name><name><surname>Rho</surname><given-names>SB</given-names></name></person-group><article-title>DAPk1 inhibits NF-kappaB activation through TNF-alpha and INF-gamma-induced apoptosis</article-title><source>Cell Signal</source><year>2012</year><volume>24</volume><fpage>1471</fpage><lpage>1477</lpage><pub-id pub-id-type="pmid">22465880</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wall</surname><given-names>L</given-names></name><name><surname>Burke</surname><given-names>F</given-names></name><name><surname>Smyth</surname><given-names>JF</given-names></name><name><surname>Balkwill</surname><given-names>F</given-names></name></person-group><article-title>The anti-proliferative activity of interferon-gamma on ovarian cancer: <italic>in vitro</italic> and <italic>in vivo</italic></article-title><source>Gynecol Oncol</source><year>2003</year><volume>88</volume><fpage>S149</fpage><lpage>151</lpage><pub-id pub-id-type="pmid">12586108</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Condello</surname><given-names>S</given-names></name><name><surname>Morgan</surname><given-names>CA</given-names></name><name><surname>Nagdas</surname><given-names>S</given-names></name><name><surname>Cao</surname><given-names>L</given-names></name><name><surname>Turek</surname><given-names>J</given-names></name><name><surname>Hurley</surname><given-names>TD</given-names></name><name><surname>Matei</surname><given-names>D</given-names></name></person-group><article-title>beta-Catenin-regulated ALDH1A1 is a target in ovarian cancer spheroids</article-title><source>Oncogene</source><year>2015</year><volume>34</volume><fpage>2297</fpage><lpage>2308</lpage><pub-id pub-id-type="pmid">24954508</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>YH</given-names></name><name><surname>Guo</surname><given-names>FJ</given-names></name><name><surname>Wang</surname><given-names>JJ</given-names></name><name><surname>Sun</surname><given-names>RL</given-names></name><name><surname>Hu</surname><given-names>JY</given-names></name><name><surname>Li</surname><given-names>GC</given-names></name></person-group><article-title>Gamma-aminobutyric acid promotes human hepatocellular carcinoma growth through overexpressed gamma-aminobutyric acid A receptor alpha 3 subunit</article-title><source>World J Gastroenterol</source><year>2008</year><volume>14</volume><fpage>7175</fpage><lpage>7182</lpage><pub-id pub-id-type="pmid">19084931</pub-id></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kurosaki</surname><given-names>A</given-names></name><name><surname>Hasegawa</surname><given-names>K</given-names></name><name><surname>Kato</surname><given-names>T</given-names></name><name><surname>Abe</surname><given-names>K</given-names></name><name><surname>Hanaoka</surname><given-names>T</given-names></name><name><surname>Miyara</surname><given-names>A</given-names></name><name><surname>O'shannessy</surname><given-names>DJ</given-names></name><name><surname>Somers</surname><given-names>EB</given-names></name><name><surname>Yasuda</surname><given-names>M</given-names></name><name><surname>Sekino</surname><given-names>T</given-names></name><name><surname>Fujiwara</surname><given-names>K</given-names></name></person-group><article-title>Serum folate receptor alpha (FRA) as a biomarker for ovarian cancer: Implications for diagnosis, prognosis and predicting its local tumor expression</article-title><source>Int J Cancer</source><year>2016</year><volume>138</volume><fpage>1994</fpage><lpage>2002</lpage><pub-id pub-id-type="doi">10.1002/ijc.29937</pub-id><pub-id pub-id-type="pmid">26595060</pub-id></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Brot</surname><given-names>S</given-names></name><name><surname>Malleval</surname><given-names>C</given-names></name><name><surname>Benetollo</surname><given-names>C</given-names></name><name><surname>Auger</surname><given-names>C</given-names></name><name><surname>Meyronet</surname><given-names>D</given-names></name><name><surname>Rogemond</surname><given-names>V</given-names></name><name><surname>Honnorat</surname><given-names>J</given-names></name><name><surname>Moradi-Ameli</surname><given-names>M</given-names></name></person-group><article-title>Identification of a new CRMP5 isoform present in the nucleus of cancer cells and enhancing their proliferation</article-title><source>Exp Cell Res</source><year>2013</year><volume>319</volume><fpage>588</fpage><lpage>599</lpage><pub-id pub-id-type="pmid">23298946</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Giovangrandi</surname><given-names>Y</given-names></name><name><surname>Parfait</surname><given-names>B</given-names></name><name><surname>Asheuer</surname><given-names>M</given-names></name><name><surname>Olivi</surname><given-names>M</given-names></name><name><surname>Lidereau</surname><given-names>R</given-names></name><name><surname>Vidaud</surname><given-names>M</given-names></name><name><surname>Bieche</surname><given-names>I</given-names></name></person-group><article-title>Analysis of the human CGB/LHB gene cluster in breast tumors by real-time quantitative RT-PCR assays</article-title><source>Cancer Lett</source><year>2001</year><volume>168</volume><fpage>93</fpage><lpage>100</lpage><pub-id pub-id-type="pmid">11368883</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>HT</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>SL</given-names></name><name><surname>Miao</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>QC</given-names></name><name><surname>Wang</surname><given-names>EH</given-names></name></person-group><article-title>TC-1 (C8orf4) expression is correlated with differentiation in ovarian carcinomas and might distinguish metastatic ovarian from metastatic colorectal carcinomas</article-title><source>Virchows Arch</source><year>2013</year><volume>462</volume><fpage>281</fpage><lpage>287</lpage><pub-id pub-id-type="pmid">23377761</pub-id></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peche</surname><given-names>LY</given-names></name><name><surname>Ladelfa</surname><given-names>MF</given-names></name><name><surname>Toledo</surname><given-names>MF</given-names></name><name><surname>Mano</surname><given-names>M</given-names></name><name><surname>Laiseca</surname><given-names>JE</given-names></name><name><surname>Schneider</surname><given-names>C</given-names></name><name><surname>Monte</surname><given-names>M</given-names></name></person-group><article-title>Human MageB2 Protein Expression Enhances E2F Transcriptional Activity, Cell Proliferation, and Resistance to Ribotoxic Stress</article-title><source>J Biol Chem</source><year>2015</year><volume>290</volume><fpage>29652</fpage><lpage>29662</lpage><pub-id pub-id-type="pmid">26468294</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Felix</surname><given-names>AS</given-names></name><name><surname>Sherman</surname><given-names>ME</given-names></name><name><surname>Hewitt</surname><given-names>SM</given-names></name><name><surname>Gunja</surname><given-names>MZ</given-names></name><name><surname>Yang</surname><given-names>HP</given-names></name><name><surname>Cora</surname><given-names>RL</given-names></name><name><surname>Boudreau</surname><given-names>V</given-names></name><name><surname>Ylaya</surname><given-names>K</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Brinton</surname><given-names>LA</given-names></name><name><surname>Wentzensen</surname><given-names>N</given-names></name></person-group><article-title>Cell-cycle protein expression in a population-based study of ovarian and endometrial cancers</article-title><source>Front Oncol</source><year>2015</year><volume>5</volume><fpage>25</fpage><pub-id pub-id-type="pmid">25709969</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fu</surname><given-names>J</given-names></name><name><surname>Lv</surname><given-names>H</given-names></name><name><surname>Guan</surname><given-names>H</given-names></name><name><surname>Ma</surname><given-names>X</given-names></name><name><surname>Ji</surname><given-names>M</given-names></name><name><surname>He</surname><given-names>N</given-names></name><name><surname>Shi</surname><given-names>B</given-names></name><name><surname>Hou</surname><given-names>P</given-names></name></person-group><article-title>Metallothionein 1G functions as a tumor suppressor in thyroid cancer through modulating the PI3K/Akt signaling pathway</article-title><source>BMC Cancer</source><year>2013</year><volume>13</volume><fpage>462</fpage><pub-id pub-id-type="pmid">24098937</pub-id></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peppelenbosch</surname><given-names>MP</given-names></name><name><surname>Spaander</surname><given-names>MC</given-names></name><name><surname>Bruno</surname><given-names>MJ</given-names></name></person-group><article-title>Glutathione peroxidase 7 prevents cancer in the oesophagus</article-title><source>Gut</source><year>2014</year><volume>63</volume><fpage>537</fpage><lpage>538</lpage><pub-id pub-id-type="pmid">23812405</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name><name><surname>Zhao</surname><given-names>H</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>F</given-names></name><name><surname>Wei</surname><given-names>Y</given-names></name><name><surname>Su</surname><given-names>J</given-names></name><name><surname>Zhang</surname><given-names>D</given-names></name><name><surname>Liu</surname><given-names>T</given-names></name><name><surname>Zhang</surname><given-names>Y</given-names></name></person-group><article-title>The identification of specific methylation patterns across different cancers</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0120361</fpage><pub-id pub-id-type="pmid">25774687</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hsieh</surname><given-names>CL</given-names></name><name><surname>Botta</surname><given-names>G</given-names></name><name><surname>Gao</surname><given-names>S</given-names></name><name><surname>Li</surname><given-names>T</given-names></name><name><surname>Van Allen</surname><given-names>EM</given-names></name><name><surname>Treacy</surname><given-names>DJ</given-names></name><name><surname>Cai</surname><given-names>C</given-names></name><name><surname>He</surname><given-names>HH</given-names></name><name><surname>Sweeney</surname><given-names>CJ</given-names></name><name><surname>Brown</surname><given-names>M</given-names></name><name><surname>Balk</surname><given-names>SP</given-names></name><name><surname>Nelson</surname><given-names>PS</given-names></name><name><surname>Garraway</surname><given-names>LA</given-names></name><etal/></person-group><article-title>PLZF, a tumor suppressor genetically lost in metastatic castration-resistant prostate cancer, is a mediator of resistance to androgen deprivation therapy</article-title><source>Cancer Res</source><year>2015</year><volume>75</volume><fpage>1944</fpage><lpage>1948</lpage><pub-id pub-id-type="pmid">25808865</pub-id></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>O'shannessy</surname><given-names>DJ</given-names></name><name><surname>Jackson</surname><given-names>SM</given-names></name><name><surname>Twine</surname><given-names>NC</given-names></name><name><surname>Hoffman</surname><given-names>BE</given-names></name><name><surname>Dezso</surname><given-names>Z</given-names></name><name><surname>Agoulnik</surname><given-names>SI</given-names></name><name><surname>Somers</surname><given-names>EB</given-names></name></person-group><article-title>Gene expression analyses support fallopian tube epithelium as the cell of origin of epithelial ovarian cancer</article-title><source>Int J Mol Sci</source><year>2013</year><volume>14</volume><fpage>13687</fpage><lpage>13703</lpage><pub-id pub-id-type="pmid">23880844</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mi</surname><given-names>R</given-names></name><name><surname>Pan</surname><given-names>C</given-names></name><name><surname>Zhou</surname><given-names>Y</given-names></name><name><surname>Liu</surname><given-names>Y</given-names></name><name><surname>Jin</surname><given-names>G</given-names></name><name><surname>Liu</surname><given-names>F</given-names></name></person-group><article-title>Identification of the metastasis potential and its associated genes in melanoma multinucleated giant cells using the PHA-ECM830 fusion method</article-title><source>Oncol Rep</source><year>2016</year><volume>35</volume><fpage>211</fpage><lpage>218</lpage><pub-id pub-id-type="pmid">26531888</pub-id></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wandzioch</surname><given-names>E</given-names></name><name><surname>Pusey</surname><given-names>M</given-names></name><name><surname>Werda</surname><given-names>A</given-names></name><name><surname>Bail</surname><given-names>S</given-names></name><name><surname>Bhaskar</surname><given-names>A</given-names></name><name><surname>Nestor</surname><given-names>M</given-names></name><name><surname>Yang</surname><given-names>JJ</given-names></name><name><surname>Rice</surname><given-names>LM</given-names></name></person-group><article-title>PME-1 modulates protein phosphatase 2A activity to promote the malignant phenotype of endometrial cancer cells</article-title><source>Cancer Res</source><year>2014</year><volume>74</volume><fpage>4295</fpage><lpage>4305</lpage><pub-id pub-id-type="pmid">24928782</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dong</surname><given-names>W</given-names></name><name><surname>Yao</surname><given-names>C</given-names></name><name><surname>Teng</surname><given-names>X</given-names></name><name><surname>Chai</surname><given-names>J</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Li</surname><given-names>B</given-names></name></person-group><article-title>MiR-140-3p suppressed cell growth and invasion by downregulating the expression of ATP8A1 in non-small cell lung cancer</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>2973</fpage><lpage>85</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-3452-9</pub-id><pub-id pub-id-type="pmid">26415732</pub-id></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gromova</surname><given-names>I</given-names></name><name><surname>Gromov</surname><given-names>P</given-names></name><name><surname>Kroman</surname><given-names>N</given-names></name><name><surname>Wielenga</surname><given-names>VT</given-names></name><name><surname>Simon</surname><given-names>R</given-names></name><name><surname>Sauter</surname><given-names>G</given-names></name><name><surname>Moreira</surname><given-names>JM</given-names></name></person-group><article-title>Immunoexpression analysis and prognostic value of BLCAP in breast cancer</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e45967</fpage><pub-id pub-id-type="pmid">23049907</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>YN</given-names></name><name><surname>Bhuwania</surname><given-names>R</given-names></name><name><surname>Gromova</surname><given-names>K</given-names></name><name><surname>Failla</surname><given-names>AV</given-names></name><name><surname>Lange</surname><given-names>T</given-names></name><name><surname>Riecken</surname><given-names>K</given-names></name><name><surname>Linder</surname><given-names>S</given-names></name><name><surname>Kneussel</surname><given-names>M</given-names></name><name><surname>Izbicki</surname><given-names>JR</given-names></name><name><surname>Windhorst</surname><given-names>S</given-names></name></person-group><article-title>Drosophila homologue of Diaphanous 1 (DIAPH1) controls the metastatic potential of colon cancer cells by regulating microtubule-dependent adhesion</article-title><source>Oncotarget</source><year>2015</year><volume>6</volume><fpage>18577</fpage><lpage>18589</lpage><pub-id pub-id-type="doi">10.18632/oncotarget.4094</pub-id><pub-id pub-id-type="pmid">26124177</pub-id></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Franco-Montoya</surname><given-names>ML</given-names></name><name><surname>Boucherat</surname><given-names>O</given-names></name><name><surname>Thibault</surname><given-names>C</given-names></name><name><surname>Chailley-Heu</surname><given-names>B</given-names></name><name><surname>Incitti</surname><given-names>R</given-names></name><name><surname>Delacourt</surname><given-names>C</given-names></name><name><surname>Bourbon</surname><given-names>JR</given-names></name></person-group><article-title>Profiling target genes of FGF18 in the postnatal mouse lung: possible relevance for alveolar development</article-title><source>Physiol Genomics</source><year>2011</year><volume>43</volume><fpage>1226</fpage><lpage>1240</lpage><pub-id pub-id-type="pmid">21878612</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Haque</surname><given-names>T</given-names></name><name><surname>Nakada</surname><given-names>S</given-names></name><name><surname>Hamdy</surname><given-names>RC</given-names></name></person-group><article-title>A review of FGF18: Its expression, signaling pathways and possible functions during embryogenesis and post-natal development</article-title><source>Histol Histopathol</source><year>2007</year><volume>22</volume><fpage>97</fpage><lpage>105</lpage><pub-id pub-id-type="pmid">17128416</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Turner</surname><given-names>N</given-names></name><name><surname>Grose</surname><given-names>R</given-names></name></person-group><article-title>Fibroblast growth factor signalling: from development to cancer</article-title><source>Nat Rev Cancer</source><year>2010</year><volume>10</volume><fpage>116</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">20094046</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miki</surname><given-names>H</given-names></name><name><surname>Okada</surname><given-names>Y</given-names></name><name><surname>Hirokawa</surname><given-names>N</given-names></name></person-group><article-title>Analysis of the kinesin superfamily: insights into structure and function</article-title><source>Trends Cell Biol</source><year>2005</year><volume>15</volume><fpage>467</fpage><lpage>476</lpage><pub-id pub-id-type="pmid">16084724</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>IM</given-names></name><name><surname>Schleicher</surname><given-names>K</given-names></name><name><surname>Porter</surname><given-names>M</given-names></name><name><surname>Swedlow</surname><given-names>JR</given-names></name></person-group><article-title>Bod1 regulates protein phosphatase 2A at mitotic kinetochores</article-title><source>Nat Commun</source><year>2013</year><volume>4</volume><fpage>2677</fpage><pub-id pub-id-type="pmid">24157919</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Porter</surname><given-names>IM</given-names></name><name><surname>McClelland</surname><given-names>SE</given-names></name><name><surname>Khoudoli</surname><given-names>GA</given-names></name><name><surname>Hunter</surname><given-names>CJ</given-names></name><name><surname>Andersen</surname><given-names>JS</given-names></name><name><surname>McAinsh</surname><given-names>AD</given-names></name><name><surname>Blow</surname><given-names>JJ</given-names></name><name><surname>Swedlow</surname><given-names>JR</given-names></name></person-group><article-title>Bod1, a novel kinetochore protein required for chromosome biorientation</article-title><source>J Cell Biol</source><year>2007</year><volume>179</volume><fpage>187</fpage><lpage>197</lpage><pub-id pub-id-type="pmid">17938248</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>Q</given-names></name><name><surname>Dalman</surname><given-names>MR</given-names></name><name><surname>Sarmah</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>S</given-names></name><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Hurlbut</surname><given-names>AK</given-names></name><name><surname>Spencer</surname><given-names>MA</given-names></name><name><surname>Pancoe</surname><given-names>L</given-names></name><name><surname>Marrs</surname><given-names>JA</given-names></name></person-group><article-title>Cell adhesion molecule cadherin-6 function in zebrafish cranial and lateral line ganglia development</article-title><source>Dev Dyn</source><year>2011</year><volume>240</volume><fpage>1716</fpage><lpage>1726</lpage><pub-id pub-id-type="pmid">21584906</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kubota</surname><given-names>F</given-names></name><name><surname>Murakami</surname><given-names>T</given-names></name><name><surname>Mogi</surname><given-names>K</given-names></name><name><surname>Yorifuji</surname><given-names>H</given-names></name></person-group><article-title>Cadherin-6 is required for zebrafish nephrogenesis during early development</article-title><source>Int J Dev Biol</source><year>2007</year><volume>51</volume><fpage>123</fpage><lpage>129</lpage><pub-id pub-id-type="pmid">17294363</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sancisi</surname><given-names>V</given-names></name><name><surname>Gandolfi</surname><given-names>G</given-names></name><name><surname>Ragazzi</surname><given-names>M</given-names></name><name><surname>Nicoli</surname><given-names>D</given-names></name><name><surname>Tamagnini</surname><given-names>I</given-names></name><name><surname>Piana</surname><given-names>S</given-names></name><name><surname>Ciarrocchi</surname><given-names>A</given-names></name></person-group><article-title>Cadherin 6 is a new RUNX2 target in TGF-beta signalling pathway</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e75489</fpage><pub-id pub-id-type="pmid">24069422</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zakin</surname><given-names>L</given-names></name><name><surname>De Robertis</surname><given-names>EM</given-names></name></person-group><article-title>Extracellular regulation of BMP signaling</article-title><source>Curr Biol</source><year>2010</year><volume>20</volume><fpage>R89</fpage><lpage>92</lpage><pub-id pub-id-type="pmid">20144774</pub-id></element-citation></ref><ref id="R54"><label>54</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hayward</surname><given-names>A</given-names></name><name><surname>Ghazal</surname><given-names>A</given-names></name><name><surname>Andersson</surname><given-names>G</given-names></name><name><surname>Andersson</surname><given-names>L</given-names></name><name><surname>Jern</surname><given-names>P</given-names></name></person-group><article-title>ZBED evolution: repeated utilization of DNA transposons as regulators of diverse host functions</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e59940</fpage><pub-id pub-id-type="pmid">23533661</pub-id></element-citation></ref><ref id="R55"><label>55</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hansford</surname><given-names>LM</given-names></name><name><surname>Smith</surname><given-names>SA</given-names></name><name><surname>Haber</surname><given-names>M</given-names></name><name><surname>Norris</surname><given-names>MD</given-names></name><name><surname>Cheung</surname><given-names>B</given-names></name><name><surname>Marshall</surname><given-names>GM</given-names></name></person-group><article-title>Cloning and characterization of the human neural cell adhesion molecule, CNTN4 (alias BIG-2)</article-title><source>Cytogenet Genome Res</source><year>2003</year><volume>101</volume><fpage>17</fpage><lpage>23</lpage><pub-id pub-id-type="pmid">14571131</pub-id></element-citation></ref><ref id="R56"><label>56</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Manderson</surname><given-names>EN</given-names></name><name><surname>Birch</surname><given-names>AH</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Mes-Masson</surname><given-names>AM</given-names></name><name><surname>Provencher</surname><given-names>D</given-names></name><name><surname>Tonin</surname><given-names>PN</given-names></name></person-group><article-title>Molecular genetic analysis of a cell adhesion molecule with homology to L1CAM, contactin 6, and contactin 4 candidate chromosome 3p26pter tumor suppressor genes in ovarian cancer</article-title><source>Int J Gynecol Cancer</source><year>2009</year><volume>19</volume><fpage>513</fpage><lpage>525</lpage><pub-id pub-id-type="pmid">19509545</pub-id></element-citation></ref><ref id="R57"><label>57</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Deng</surname><given-names>Y</given-names></name><name><surname>Chen</surname><given-names>C</given-names></name><name><surname>Hua</surname><given-names>M</given-names></name><name><surname>Xi</surname><given-names>Q</given-names></name><name><surname>Liu</surname><given-names>R</given-names></name><name><surname>Yang</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>J</given-names></name><name><surname>Zhong</surname><given-names>J</given-names></name><name><surname>Tang</surname><given-names>M</given-names></name><name><surname>Lu</surname><given-names>S</given-names></name><name><surname>Tang</surname><given-names>C</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name></person-group><article-title>Annexin A2 plays a critical role in epithelial ovarian cancer</article-title><source>Arch Gynecol Obstet</source><year>2015</year><volume>292</volume><fpage>175</fpage><lpage>182</lpage><pub-id pub-id-type="pmid">25547062</pub-id></element-citation></ref><ref id="R58"><label>58</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schroder</surname><given-names>WA</given-names></name><name><surname>Major</surname><given-names>L</given-names></name><name><surname>Suhrbier</surname><given-names>A</given-names></name></person-group><article-title>The role of SerpinB2 in immunity</article-title><source>Crit Rev Immunol</source><year>2011</year><volume>31</volume><fpage>15</fpage><lpage>30</lpage><pub-id pub-id-type="pmid">21395508</pub-id></element-citation></ref><ref id="R59"><label>59</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Croucher</surname><given-names>DR</given-names></name><name><surname>Saunders</surname><given-names>DN</given-names></name><name><surname>Lobov</surname><given-names>S</given-names></name><name><surname>Ranson</surname><given-names>M</given-names></name></person-group><article-title>Revisiting the biological roles of PAI2 (SERPINB2) in cancer</article-title><source>Nat Rev Cancer</source><year>2008</year><volume>8</volume><fpage>535</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">18548086</pub-id></element-citation></ref><ref id="R60"><label>60</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chambers</surname><given-names>SK</given-names></name><name><surname>Ivins</surname><given-names>CM</given-names></name><name><surname>Carcangiu</surname><given-names>ML</given-names></name></person-group><article-title>Expression of plasminogen activator inhibitor-2 in epithelial ovarian cancer: a favorable prognostic factor related to the actions of CSF-1</article-title><source>Int J Cancer</source><year>1997</year><volume>74</volume><fpage>571</fpage><lpage>575</lpage><pub-id pub-id-type="pmid">9421350</pub-id></element-citation></ref><ref id="R61"><label>61</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>M</given-names></name><name><surname>Zhao</surname><given-names>J</given-names></name><name><surname>Chen</surname><given-names>K</given-names></name><name><surname>Bian</surname><given-names>X</given-names></name><name><surname>Wang</surname><given-names>C</given-names></name><name><surname>Shi</surname><given-names>Y</given-names></name><name><surname>Wang</surname><given-names>JM</given-names></name></person-group><article-title>G protein-coupled receptor FPR1 as a pharmacologic target in inflammation and human glioblastoma</article-title><source>Int Immunopharmacol</source><year>2012</year><volume>14</volume><fpage>283</fpage><lpage>288</lpage><pub-id pub-id-type="pmid">22863814</pub-id></element-citation></ref><ref id="R62"><label>62</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Prevete</surname><given-names>N</given-names></name><name><surname>Liotti</surname><given-names>F</given-names></name><name><surname>Marone</surname><given-names>G</given-names></name><name><surname>Melillo</surname><given-names>RM</given-names></name><name><surname>de Paulis</surname><given-names>A</given-names></name></person-group><article-title>Formyl peptide receptors at the interface of inflammation, angiogenesis and tumor growth</article-title><source>Pharmacol Res</source><year>2015</year><volume>102</volume><fpage>184</fpage><lpage>191</lpage><pub-id pub-id-type="pmid">26466865</pub-id></element-citation></ref><ref id="R63"><label>63</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Loddo</surname><given-names>M</given-names></name><name><surname>Andryszkiewicz</surname><given-names>J</given-names></name><name><surname>Rodriguez-Acebes</surname><given-names>S</given-names></name><name><surname>Stoeber</surname><given-names>K</given-names></name><name><surname>Jones</surname><given-names>A</given-names></name><name><surname>Dafou</surname><given-names>D</given-names></name><name><surname>Apostolidou</surname><given-names>S</given-names></name><name><surname>Wollenschlaeger</surname><given-names>A</given-names></name><name><surname>Widschwendter</surname><given-names>M</given-names></name><name><surname>Sainsbury</surname><given-names>R</given-names></name><name><surname>Tudzarova</surname><given-names>S</given-names></name><name><surname>Williams</surname><given-names>GH</given-names></name></person-group><article-title>Pregnancy-associated plasma protein A regulates mitosis and is epigenetically silenced in breast cancer</article-title><source>J Pathol</source><year>2014</year><volume>233</volume><fpage>344</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">24931331</pub-id></element-citation></ref><ref id="R64"><label>64</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ghosh</surname><given-names>M</given-names></name><name><surname>Shen</surname><given-names>Z</given-names></name><name><surname>Schaefer</surname><given-names>TM</given-names></name><name><surname>Fahey</surname><given-names>JV</given-names></name><name><surname>Gupta</surname><given-names>P</given-names></name><name><surname>Wira</surname><given-names>CR</given-names></name></person-group><article-title>CCL20/MIP3alpha is a novel anti-HIV-1 molecule of the human female reproductive tract</article-title><source>Am J Reprod Immunol</source><year>2009</year><volume>62</volume><fpage>60</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">19527233</pub-id></element-citation></ref><ref id="R65"><label>65</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Son</surname><given-names>DS</given-names></name><name><surname>Kabir</surname><given-names>SM</given-names></name><name><surname>Dong</surname><given-names>Y</given-names></name><name><surname>Lee</surname><given-names>E</given-names></name><name><surname>Adunyah</surname><given-names>SE</given-names></name></person-group><article-title>Characteristics of chemokine signatures elicited by EGF and TNF in ovarian cancer cells</article-title><source>J Inflamm (Lond)</source><year>2013</year><volume>10</volume><fpage>25</fpage><pub-id pub-id-type="pmid">23800251</pub-id></element-citation></ref><ref id="R66"><label>66</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Couderc</surname><given-names>B</given-names></name><name><surname>Pradines</surname><given-names>A</given-names></name><name><surname>Rafii</surname><given-names>A</given-names></name><name><surname>Golzio</surname><given-names>M</given-names></name><name><surname>Deviers</surname><given-names>A</given-names></name><name><surname>Allal</surname><given-names>C</given-names></name><name><surname>Berg</surname><given-names>D</given-names></name><name><surname>Penary</surname><given-names>M</given-names></name><name><surname>Teissie</surname><given-names>J</given-names></name><name><surname>Favre</surname><given-names>G</given-names></name></person-group><article-title><italic>In vivo</italic> restoration of RhoB expression leads to ovarian tumor regression</article-title><source>Cancer Gene Ther</source><year>2008</year><volume>15</volume><fpage>456</fpage><lpage>464</lpage><pub-id pub-id-type="pmid">18340357</pub-id></element-citation></ref><ref id="R67"><label>67</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nash</surname><given-names>MA</given-names></name><name><surname>Deavers</surname><given-names>MT</given-names></name><name><surname>Freedman</surname><given-names>RS</given-names></name></person-group><article-title>The expression of decorin in human ovarian tumors</article-title><source>Clin Cancer Res</source><year>2002</year><volume>8</volume><fpage>1754</fpage><lpage>1760</lpage><pub-id pub-id-type="pmid">12060613</pub-id></element-citation></ref><ref id="R68"><label>68</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>Y</given-names></name><name><surname>Sun</surname><given-names>L</given-names></name><name><surname>Zou</surname><given-names>W</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Wang</surname><given-names>W</given-names></name><name><surname>Yun</surname><given-names>X</given-names></name><name><surname>Gu</surname><given-names>J</given-names></name></person-group><article-title>Prosaposin, a regulator of estrogen receptor alpha, promotes breast cancer growth</article-title><source>Cancer Sci</source><year>2012</year><volume>103</volume><fpage>1820</fpage><lpage>1825</lpage><pub-id pub-id-type="pmid">22738294</pub-id></element-citation></ref><ref id="R69"><label>69</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name><name><surname>Oliva</surname><given-names>E</given-names></name><name><surname>Kim</surname><given-names>SH</given-names></name><name><surname>Mohapatra</surname><given-names>G</given-names></name><name><surname>Birrer</surname><given-names>MJ</given-names></name></person-group><article-title>FGF18 as a prognostic and therapeutic biomarker in ovarian cancer</article-title><source>J Clin Invest</source><year>2013</year><volume>123</volume><fpage>4435</fpage><lpage>4448</lpage><pub-id pub-id-type="pmid">24018557</pub-id></element-citation></ref><ref id="R70"><label>70</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tan</surname><given-names>H</given-names></name><name><surname>He</surname><given-names>Q</given-names></name><name><surname>Gong</surname><given-names>G</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>J</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name><name><surname>Zhu</surname><given-names>D</given-names></name><name><surname>Wu</surname><given-names>X</given-names></name></person-group><article-title>miR-382 inhibits migration and invasion by targeting ROR1 through regulating EMT in ovarian cancer</article-title><source>Int J Oncol</source><year>2016</year><volume>48</volume><fpage>181</fpage><lpage>190</lpage><pub-id pub-id-type="pmid">26575700</pub-id></element-citation></ref><ref id="R71"><label>71</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lv</surname><given-names>Q</given-names></name><name><surname>Shen</surname><given-names>R</given-names></name><name><surname>Wang</surname><given-names>J</given-names></name></person-group><article-title>RBPJ inhibition impairs the growth of lung cancer</article-title><source>Tumour Biol</source><year>2015</year><volume>36</volume><fpage>3751</fpage><lpage>3756</lpage><pub-id pub-id-type="pmid">25589461</pub-id></element-citation></ref><ref id="R72"><label>72</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gao</surname><given-names>Q</given-names></name><name><surname>Steine</surname><given-names>EJ</given-names></name><name><surname>Barrasa</surname><given-names>MI</given-names></name><name><surname>Hockemeyer</surname><given-names>D</given-names></name><name><surname>Pawlak</surname><given-names>M</given-names></name><name><surname>Fu</surname><given-names>D</given-names></name><name><surname>Reddy</surname><given-names>S</given-names></name><name><surname>Bell</surname><given-names>GW</given-names></name><name><surname>Jaenisch</surname><given-names>R</given-names></name></person-group><article-title>Deletion of the de novo DNA methyltransferase Dnmt3a promotes lung tumor progression</article-title><source>Proc Natl Acad Sci U S A</source><year>2011</year><volume>108</volume><fpage>18061</fpage><lpage>18066</lpage><pub-id pub-id-type="pmid">22011581</pub-id></element-citation></ref><ref id="R73"><label>73</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yoshioka</surname><given-names>S</given-names></name><name><surname>King</surname><given-names>ML</given-names></name><name><surname>Ran</surname><given-names>S</given-names></name><name><surname>Okuda</surname><given-names>H</given-names></name><name><surname>MacLean</surname><given-names>JA</given-names><suffix>2nd</suffix></name><name><surname>McAsey</surname><given-names>ME</given-names></name><name><surname>Sugino</surname><given-names>N</given-names></name><name><surname>Brard</surname><given-names>L</given-names></name><name><surname>Watabe</surname><given-names>K</given-names></name><name><surname>Hayashi</surname><given-names>K</given-names></name></person-group><article-title>WNT7A regulates tumor growth and progression in ovarian cancer through the WNT/beta-catenin pathway</article-title><source>Mol Cancer Res</source><year>2012</year><volume>10</volume><fpage>469</fpage><lpage>482</lpage><pub-id pub-id-type="pmid">22232518</pub-id></element-citation></ref><ref id="R74"><label>74</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Weidle</surname><given-names>UH</given-names></name><name><surname>Evtimova</surname><given-names>V</given-names></name><name><surname>Alberti</surname><given-names>S</given-names></name><name><surname>Guerra</surname><given-names>E</given-names></name><name><surname>Fersis</surname><given-names>N</given-names></name><name><surname>Kaul</surname><given-names>S</given-names></name></person-group><article-title>Cell growth stimulation by CRASH, an asparaginase-like protein overexpressed in human tumors and metastatic breast cancers</article-title><source>Anticancer Res</source><year>2009</year><volume>29</volume><fpage>951</fpage><lpage>963</lpage><pub-id pub-id-type="pmid">19414332</pub-id></element-citation></ref><ref id="R75"><label>75</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Roider</surname><given-names>HG</given-names></name><name><surname>Manke</surname><given-names>T</given-names></name><name><surname>O'Keeffe</surname><given-names>S</given-names></name><name><surname>Vingron</surname><given-names>M</given-names></name><name><surname>Haas</surname><given-names>SA</given-names></name></person-group><article-title>PASTAA: identifying transcription factors associated with sets of co-regulated genes</article-title><source>Bioinformatics</source><year>2009</year><volume>25</volume><fpage>435</fpage><lpage>442</lpage><pub-id pub-id-type="pmid">19073590</pub-id></element-citation></ref><ref id="R76"><label>76</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nolen</surname><given-names>BM</given-names></name><name><surname>Lokshin</surname><given-names>AE</given-names></name></person-group><article-title>Biomarker testing for ovarian cancer: clinical utility of multiplex assays</article-title><source>Mol Diagn Ther</source><year>2013</year><volume>17</volume><fpage>139</fpage><lpage>146</lpage><pub-id pub-id-type="pmid">23552992</pub-id></element-citation></ref><ref id="R77"><label>77</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jiang</surname><given-names>W</given-names></name><name><surname>Huang</surname><given-names>R</given-names></name><name><surname>Duan</surname><given-names>C</given-names></name><name><surname>Fu</surname><given-names>L</given-names></name><name><surname>Xi</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>Y</given-names></name><name><surname>Yang</surname><given-names>WM</given-names></name><name><surname>Yang</surname><given-names>D</given-names></name><name><surname>Yang</surname><given-names>DH</given-names></name><name><surname>Huang</surname><given-names>RP</given-names></name></person-group><article-title>Identification of five serum protein markers for detection of ovarian cancer by antibody arrays</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e76795</fpage><pub-id pub-id-type="pmid">24116163</pub-id></element-citation></ref><ref id="R78"><label>78</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaspric</surname><given-names>N</given-names></name><name><surname>Picard</surname><given-names>B</given-names></name><name><surname>Reichstadt</surname><given-names>M</given-names></name><name><surname>Tournayre</surname><given-names>J</given-names></name><name><surname>Bonnet</surname><given-names>M</given-names></name></person-group><article-title>ProteINSIDE to Easily Investigate Proteomics Data from Ruminants: Application to Mine Proteome of Adipose and Muscle Tissues in Bovine Foetuses</article-title><source>PLoS One</source><year>2015</year><volume>10</volume><fpage>e0128086</fpage><pub-id pub-id-type="pmid">26000831</pub-id></element-citation></ref><ref id="R79"><label>79</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Szczerba</surname><given-names>A</given-names></name><name><surname>Sliwa</surname><given-names>A</given-names></name><name><surname>Kubiczak</surname><given-names>M</given-names></name><name><surname>Nowak-Markwitz</surname><given-names>E</given-names></name><name><surname>Jankowska</surname><given-names>A</given-names></name></person-group><article-title>Human chorionic gonadotropin beta subunit affects the expression of apoptosis-regulating factors in ovarian cancer</article-title><source>Oncol Rep</source><year>2016</year><volume>35</volume><fpage>538</fpage><lpage>545</lpage><pub-id pub-id-type="pmid">26530886</pub-id></element-citation></ref><ref id="R80"><label>80</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lim</surname><given-names>W</given-names></name><name><surname>Jeong</surname><given-names>W</given-names></name><name><surname>Kim</surname><given-names>J</given-names></name><name><surname>Ka</surname><given-names>H</given-names></name><name><surname>Bazer</surname><given-names>FW</given-names></name><name><surname>Han</surname><given-names>JY</given-names></name><name><surname>Song</surname><given-names>G</given-names></name></person-group><article-title>Differential expression of secreted phosphoprotein 1 in response to estradiol-17beta and in ovarian tumors in chickens</article-title><source>Biochem Biophys Res Commun</source><year>2012</year><volume>422</volume><fpage>494</fpage><lpage>500</lpage><pub-id pub-id-type="pmid">22588173</pub-id></element-citation></ref><ref id="R81"><label>81</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Douglas</surname><given-names>JB</given-names></name><name><surname>Silverman</surname><given-names>DT</given-names></name><name><surname>Pollak</surname><given-names>MN</given-names></name><name><surname>Tao</surname><given-names>Y</given-names></name><name><surname>Soliman</surname><given-names>AS</given-names></name><name><surname>Stolzenberg-Solomon</surname><given-names>RZ</given-names></name></person-group><article-title>Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2010</year><volume>19</volume><fpage>2298</fpage><lpage>2306</lpage><pub-id pub-id-type="pmid">20699371</pub-id></element-citation></ref><ref id="R82"><label>82</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>He</surname><given-names>LH</given-names></name><name><surname>Ma</surname><given-names>Q</given-names></name><name><surname>Shi</surname><given-names>YH</given-names></name><name><surname>Ge</surname><given-names>J</given-names></name><name><surname>Zhao</surname><given-names>HM</given-names></name><name><surname>Li</surname><given-names>SF</given-names></name><name><surname>Tong</surname><given-names>ZS</given-names></name></person-group><article-title>CHL1 is involved in human breast tumorigenesis and progression</article-title><source>Biochem Biophys Res Commun</source><year>2013</year><volume>438</volume><fpage>433</fpage><lpage>438</lpage><pub-id pub-id-type="pmid">23906755</pub-id></element-citation></ref><ref id="R83"><label>83</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Epping</surname><given-names>MT</given-names></name><name><surname>Wang</surname><given-names>L</given-names></name><name><surname>Edel</surname><given-names>MJ</given-names></name><name><surname>Carlee</surname><given-names>L</given-names></name><name><surname>Hernandez</surname><given-names>M</given-names></name><name><surname>Bernards</surname><given-names>R</given-names></name></person-group><article-title>The human tumor antigen PRAME is a dominant repressor of retinoic acid receptor signaling</article-title><source>Cell</source><year>2005</year><volume>122</volume><fpage>835</fpage><lpage>847</lpage><pub-id pub-id-type="pmid">16179254</pub-id></element-citation></ref><ref id="R84"><label>84</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tagliaferri</surname><given-names>D</given-names></name><name><surname>De Angelis</surname><given-names>MT</given-names></name><name><surname>Russo</surname><given-names>NA</given-names></name><name><surname>Marotta</surname><given-names>M</given-names></name><name><surname>Ceccarelli</surname><given-names>M</given-names></name><name><surname>Del Vecchio</surname><given-names>L</given-names></name><name><surname>De Felice</surname><given-names>M</given-names></name><name><surname>Falco</surname><given-names>G</given-names></name></person-group><article-title>Retinoic Acid Specifically Enhances Embryonic Stem Cell Metastate Marked by Zscan4</article-title><source>PLoS One</source><year>2016</year><volume>11</volume><fpage>e0147683</fpage><pub-id pub-id-type="pmid">26840068</pub-id></element-citation></ref><ref id="R85"><label>85</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kewitz</surname><given-names>S</given-names></name><name><surname>Staege</surname><given-names>MS</given-names></name></person-group><article-title>Knock-down of PRAME increases retinoic acid signaling and cytotoxic drug sensitivity of Hodgkin lymphoma cells</article-title><source>PLoS One</source><year>2013</year><volume>8</volume><fpage>e55897</fpage><pub-id pub-id-type="pmid">23409080</pub-id></element-citation></ref><ref id="R86"><label>86</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schaner</surname><given-names>ME</given-names></name><name><surname>Ross</surname><given-names>DT</given-names></name><name><surname>Ciaravino</surname><given-names>G</given-names></name><name><surname>Sorlie</surname><given-names>T</given-names></name><name><surname>Troyanskaya</surname><given-names>O</given-names></name><name><surname>Diehn</surname><given-names>M</given-names></name><name><surname>Wang</surname><given-names>YC</given-names></name><name><surname>Duran</surname><given-names>GE</given-names></name><name><surname>Sikic</surname><given-names>TL</given-names></name><name><surname>Caldeira</surname><given-names>S</given-names></name><name><surname>Skomedal</surname><given-names>H</given-names></name><name><surname>Tu</surname><given-names>IP</given-names></name><name><surname>Hernandez-Boussard</surname><given-names>T</given-names></name><etal/></person-group><article-title>Gene expression patterns in ovarian carcinomas</article-title><source>Mol Biol Cell</source><year>2003</year><volume>14</volume><fpage>4376</fpage><lpage>4386</lpage><pub-id pub-id-type="pmid">12960427</pub-id></element-citation></ref><ref id="R87"><label>87</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bowen</surname><given-names>NJ</given-names></name><name><surname>Logani</surname><given-names>S</given-names></name><name><surname>Dickerson</surname><given-names>EB</given-names></name><name><surname>Kapa</surname><given-names>LB</given-names></name><name><surname>Akhtar</surname><given-names>M</given-names></name><name><surname>Benigno</surname><given-names>BB</given-names></name><name><surname>McDonald</surname><given-names>JF</given-names></name></person-group><article-title>Emerging roles for PAX8 in ovarian cancer and endosalpingeal development</article-title><source>Gynecol Oncol</source><year>2007</year><volume>104</volume><fpage>331</fpage><lpage>337</lpage><pub-id pub-id-type="pmid">17064757</pub-id></element-citation></ref><ref id="R88"><label>88</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>El-Gendi</surname><given-names>S</given-names></name><name><surname>Abdelzaher</surname><given-names>E</given-names></name><name><surname>Mostafa</surname><given-names>MF</given-names></name><name><surname>Sheasha</surname><given-names>GA</given-names></name></person-group><article-title>FGF18 as a potential biomarker in serous and mucinous ovarian tumors</article-title><source>Tumour Biol</source><year>2016</year><volume>37</volume><fpage>3173</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1007/s13277-015-4129-0</pub-id><pub-id pub-id-type="pmid">26427667</pub-id></element-citation></ref><ref id="R89"><label>89</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Birrer</surname><given-names>MJ</given-names></name><name><surname>Johnson</surname><given-names>ME</given-names></name><name><surname>Hao</surname><given-names>K</given-names></name><name><surname>Wong</surname><given-names>KK</given-names></name><name><surname>Park</surname><given-names>DC</given-names></name><name><surname>Bell</surname><given-names>A</given-names></name><name><surname>Welch</surname><given-names>WR</given-names></name><name><surname>Berkowitz</surname><given-names>RS</given-names></name><name><surname>Mok</surname><given-names>SC</given-names></name></person-group><article-title>Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas</article-title><source>J Clin Oncol</source><year>2007</year><volume>25</volume><fpage>2281</fpage><lpage>2287</lpage><pub-id pub-id-type="pmid">17538174</pub-id></element-citation></ref><ref id="R90"><label>90</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vathipadiekal</surname><given-names>V</given-names></name><name><surname>Wang</surname><given-names>V</given-names></name><name><surname>Wei</surname><given-names>W</given-names></name><name><surname>Waldron</surname><given-names>L</given-names></name><name><surname>Drapkin</surname><given-names>R</given-names></name><name><surname>Gillette</surname><given-names>M</given-names></name><name><surname>Skates</surname><given-names>S</given-names></name><name><surname>Birrer</surname><given-names>M</given-names></name></person-group><article-title>Creation of a Human Secretome: A Novel Composite Library of Human Secreted Proteins: Validation Using Ovarian Cancer Gene Expression Data and a Virtual Secretome Array</article-title><source>Clin Cancer Res</source><year>2015</year><volume>21</volume><fpage>4960</fpage><lpage>4969</lpage><pub-id pub-id-type="pmid">25944803</pub-id></element-citation></ref><ref id="R91"><label>91</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Tang</surname><given-names>SN</given-names></name><name><surname>Zheng</surname><given-names>W</given-names></name></person-group><article-title>Fallopian tube secretory cell expansion: a sensitive biomarker for ovarian serous carcinogenesis</article-title><source>Am J Transl Res</source><year>2015</year><volume>7</volume><fpage>2082</fpage><lpage>2090</lpage><pub-id pub-id-type="pmid">26692952</pub-id></element-citation></ref><ref id="R92"><label>92</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Quartuccio</surname><given-names>SM</given-names></name><name><surname>Karthikeyan</surname><given-names>S</given-names></name><name><surname>Eddie</surname><given-names>SL</given-names></name><name><surname>Lantvit</surname><given-names>DD</given-names></name><name><surname>E</surname><given-names>Oh</given-names></name><name><surname>Modi</surname><given-names>DA</given-names></name><name><surname>Wei</surname><given-names>JJ</given-names></name><name><surname>Burdette</surname><given-names>JE</given-names></name></person-group><article-title>Mutant p53 expression in fallopian tube epithelium drives cell migration</article-title><source>Int J Cancer</source><year>2015</year><volume>137</volume><fpage>1528</fpage><lpage>1538</lpage><pub-id pub-id-type="pmid">25810107</pub-id></element-citation></ref><ref id="R93"><label>93</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Munakata</surname><given-names>S</given-names></name><name><surname>Yamamoto</surname><given-names>T</given-names></name></person-group><article-title>Incidence of serous tubal intraepithelial carcinoma (STIC) by algorithm classification in serous ovarian tumor associated with PAX8 expression in tubal epithelia: a study of single institution in Japan</article-title><source>Int J Gynecol Pathol</source><year>2015</year><volume>34</volume><fpage>9</fpage><lpage>18</lpage><pub-id pub-id-type="pmid">25473747</pub-id></element-citation></ref><ref id="R94"><label>94</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Medeiros</surname><given-names>F</given-names></name><name><surname>Muto</surname><given-names>MG</given-names></name><name><surname>Lee</surname><given-names>Y</given-names></name><name><surname>Elvin</surname><given-names>JA</given-names></name><name><surname>Callahan</surname><given-names>MJ</given-names></name><name><surname>Feltmate</surname><given-names>C</given-names></name><name><surname>Garber</surname><given-names>JE</given-names></name><name><surname>Cramer</surname><given-names>DW</given-names></name><name><surname>Crum</surname><given-names>CP</given-names></name></person-group><article-title>The tubal fimbria is a preferred site for early adenocarcinoma in women with familial ovarian cancer syndrome</article-title><source>Am J Surg Pathol</source><year>2006</year><volume>30</volume><fpage>230</fpage><lpage>236</lpage><pub-id pub-id-type="pmid">16434898</pub-id></element-citation></ref><ref id="R95"><label>95</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D'Antonio</surname><given-names>M</given-names></name><name><surname>D'Onorio De Meo</surname><given-names>P</given-names></name><name><surname>Pallocca</surname><given-names>M</given-names></name><name><surname>Picardi</surname><given-names>E</given-names></name><name><surname>D'Erchia</surname><given-names>AM</given-names></name><name><surname>Calogero</surname><given-names>RA</given-names></name><name><surname>Castrignano</surname><given-names>T</given-names></name><name><surname>Pesole</surname><given-names>G</given-names></name></person-group><article-title>RAP: RNA-Seq Analysis Pipeline, a new cloud-based NGS web application</article-title><source>BMC Genomics</source><year>2015</year><volume>16</volume><fpage>S3</fpage></element-citation></ref><ref id="R96"><label>96</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Patel</surname><given-names>RK</given-names></name><name><surname>Jain</surname><given-names>M</given-names></name></person-group><article-title>NGS QC Toolkit: a toolkit for quality control of next generation sequencing data</article-title><source>PLoS One</source><year>2012</year><volume>7</volume><fpage>e30619</fpage><pub-id pub-id-type="pmid">22312429</pub-id></element-citation></ref><ref id="R97"><label>97</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kim</surname><given-names>D</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Pimentel</surname><given-names>H</given-names></name><name><surname>Kelley</surname><given-names>R</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name></person-group><article-title>TopHat2: accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions</article-title><source>Genome Biol</source><year>2013</year><volume>14</volume><fpage>R36</fpage><pub-id pub-id-type="pmid">23618408</pub-id></element-citation></ref><ref id="R98"><label>98</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Williams</surname><given-names>BA</given-names></name><name><surname>Pertea</surname><given-names>G</given-names></name><name><surname>Mortazavi</surname><given-names>A</given-names></name><name><surname>Kwan</surname><given-names>G</given-names></name><name><surname>van Baren</surname><given-names>MJ</given-names></name><name><surname>Salzberg</surname><given-names>SL</given-names></name><name><surname>Wold</surname><given-names>BJ</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><article-title>Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation</article-title><source>Nat Biotechnol</source><year>2010</year><volume>28</volume><fpage>511</fpage><lpage>515</lpage><pub-id pub-id-type="pmid">20436464</pub-id></element-citation></ref><ref id="R99"><label>99</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Trapnell</surname><given-names>C</given-names></name><name><surname>Hendrickson</surname><given-names>DG</given-names></name><name><surname>Sauvageau</surname><given-names>M</given-names></name><name><surname>Goff</surname><given-names>L</given-names></name><name><surname>Rinn</surname><given-names>JL</given-names></name><name><surname>Pachter</surname><given-names>L</given-names></name></person-group><article-title>Differential analysis of gene regulation at transcript resolution with RNA-seq</article-title><source>Nat Biotechnol</source><year>2013</year><volume>31</volume><fpage>46</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">23222703</pub-id></element-citation></ref><ref id="R100"><label>100</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Di Palma</surname><given-names>T</given-names></name><name><surname>Conti</surname><given-names>A</given-names></name><name><surname>de Cristofaro</surname><given-names>T</given-names></name><name><surname>Scala</surname><given-names>S</given-names></name><name><surname>Nitsch</surname><given-names>L</given-names></name><name><surname>Zannini</surname><given-names>M</given-names></name></person-group><article-title>Identification of novel Pax8 targets in FRTL-5 thyroid cells by gene silencing and expression microarray analysis</article-title><source>PLoS One</source><year>2011</year><volume>6</volume><fpage>e25162</fpage><pub-id pub-id-type="pmid">21966443</pub-id></element-citation></ref><ref id="R101"><label>101</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tabas-Madrid</surname><given-names>D</given-names></name><name><surname>Nogales-Cadenas</surname><given-names>R</given-names></name><name><surname>Pascual-Montano</surname><given-names>A</given-names></name></person-group><article-title>GeneCodis3: a non-redundant and modular enrichment analysis tool for functional genomics</article-title><source>Nucleic Acids Res</source><year>2012</year><volume>40</volume><fpage>W478</fpage><lpage>483</lpage><pub-id pub-id-type="pmid">22573175</pub-id></element-citation></ref><ref id="R102"><label>102</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nogales-Cadenas</surname><given-names>R</given-names></name><name><surname>Carmona-Saez</surname><given-names>P</given-names></name><name><surname>Vazquez</surname><given-names>M</given-names></name><name><surname>Vicente</surname><given-names>C</given-names></name><name><surname>Yang</surname><given-names>X</given-names></name><name><surname>Tirado</surname><given-names>F</given-names></name><name><surname>Carazo</surname><given-names>JM</given-names></name><name><surname>Pascual-Montano</surname><given-names>A</given-names></name></person-group><article-title>GeneCodis: interpreting gene lists through enrichment analysis and integration of diverse biological information</article-title><source>Nucleic Acids Res</source><year>2009</year><volume>37</volume><fpage>W317</fpage><lpage>322</lpage><pub-id pub-id-type="pmid">19465387</pub-id></element-citation></ref><ref id="R103"><label>103</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Carmona-Saez</surname><given-names>P</given-names></name><name><surname>Chagoyen</surname><given-names>M</given-names></name><name><surname>Tirado</surname><given-names>F</given-names></name><name><surname>Carazo</surname><given-names>JM</given-names></name><name><surname>Pascual-Montano</surname><given-names>A</given-names></name></person-group><article-title>GENECODIS: a web-based tool for finding significant concurrent annotations in gene lists</article-title><source>Genome Biol</source><year>2007</year><volume>8</volume><fpage>R3</fpage><pub-id pub-id-type="pmid">17204154</pub-id></element-citation></ref></ref-list></back></article>